Evolent Health (EVH) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2020	Aug. 01, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-37415
Entity Registrant Name	Evolent Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0454912
Entity Address, Address Line One	800 N. Glebe Road
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Arlington
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22203
City Area Code	571
Local Phone Number	389-6000
Title of 12(b) Security	Class A Common Stock of Evolent Health, Inc., par value $0.01 per share
Trading Symbol	EVH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		85,617,165
Entity Central Index Key	0001628908
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents		$ 98,272	$ 101,008
Restricted cash and restricted investments		46,894	20,080
Accounts receivable, net	[1]	95,839	75,667
Prepaid expenses and other current assets	[1]	30,473	28,488
Investments, at amortized cost		834	1,807
Contract assets		2,346	1,751
Total current assets		274,658	228,801
Restricted cash and restricted investments		8,759	8,260
Investments, at amortized cost		16,073	16,751
Investments in and advances to equity method investees		100,216	122,618
Property and equipment, net		88,555	85,155
Right-of-use assets - operating		66,113	72,173
Customer advance for regulatory capital requirements, net of allowances	[1]	39,955	40,000
Prepaid expenses and other noncurrent assets, net of allowances	[1]	6,437	6,253
Contract assets		47	999
Contract cost assets		31,713	36,482
Intangible assets, net		282,913	308,459
Goodwill		354,695	572,064
Total assets		1,270,134	1,498,015
Current liabilities:
Accounts payable	[1]	73,691	37,488
Accrued liabilities	[1]	35,305	33,343
Operating lease liability - current		7,474	6,269
Accrued compensation and employee benefits		20,996	34,691
Deferred revenue		13,247	19,828
Reserve for claims and performance-based arrangements	[1]	94,409	61,150
Total current liabilities		245,122	192,769
Long-term debt, net of discount		299,746	293,667
Other long-term liabilities		10,101	11,732
Operating lease liabilities - noncurrent		66,975	68,858
Deferred tax liabilities, net		1,326	1,942
Total liabilities		623,270	568,968
Commitments and Contingencies (See Note 10)
Shareholders' Equity (Deficit)
Additional paid-in-capital		1,183,605	1,173,708
Accumulated other comprehensive income (loss)		(391)	(234)
Retained earnings (accumulated deficit)		(537,205)	(251,962)
Total shareholders' equity attributable to Evolent Health, Inc.		646,864	922,358
Non-controlling interests		0	6,689
Total shareholders' equity (deficit)		646,864	929,047
Total liabilities and shareholders' equity (deficit)		1,270,134	1,498,015
Class A Common Stock
Shareholders' Equity (Deficit)
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 85,456,905 and 84,588,629 shares issued and outstanding, respectively		$ 855	$ 846
[1]	See Note 18 for amounts attributable to related parties included in these line items.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	85,456,905	84,588,629
Common stock, shares outstanding (in shares)	85,456,905	84,588,629

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue
Total revenue		$ 238,632	$ 191,959	$ 485,917	$ 389,715
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)	[1]	165,812	108,383	341,465	225,824
Claims expenses		18,144	36,085	41,811	73,842
Selling, general and administrative expenses	[1]	50,511	66,932	105,209	141,770
Depreciation and amortization expenses		15,778	15,292	31,916	29,558
(Gain) loss on disposal of assets		0	(9,600)	6,447	(9,600)
Goodwill impairment		215,100	0	215,100	0
Change in fair value of contingent consideration and indemnification asset		756	100	(3,062)	200
Total operating expenses		466,101	217,192	738,886	461,594
Operating loss		(227,469)	(25,233)	(252,969)	(71,879)
Interest income		842	842	1,761	1,902
Interest expense		(6,293)	(3,620)	(12,578)	(7,182)
Impairment of equity method investments		0	0	(47,133)	0
Gain (loss) from equity method investees		25,143	(1,904)	24,731	(2,328)
Other income (expense), net		352	(587)	281	(160)
Loss before income taxes and non-controlling interests		(207,425)	(30,502)	(285,907)	(79,647)
Provision (benefit) for income taxes		(3,904)	1,398	(3,634)	902
Net loss		(203,521)	(31,900)	(282,273)	(80,549)
Net loss attributable to non-controlling interests		0	(285)	0	(2,195)
Net loss attributable to common shareholders of Evolent Health, Inc.		$ (203,521)	$ (31,615)	$ (282,273)	$ (78,354)
Loss per common share
Basic and diluted (in dollars per share)		$ (2.38)	$ (0.38)	$ (3.32)	$ (0.97)
Weighted-average common shares outstanding
Basic and diluted (in shares)		85,349	82,289	84,977	80,820
Comprehensive loss
Net loss		$ (203,521)	$ (31,900)	$ (282,273)	$ (80,549)
Other comprehensive loss, net of taxes, related to:
Foreign currency translation adjustment		(4)	11	(157)	35
Total comprehensive loss		(203,525)	(31,889)	(282,430)	(80,514)
Total comprehensive loss attributable to non-controlling interests		0	(285)	0	(2,195)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.		(203,525)	(31,604)	(282,430)	(78,319)
Transformation services
Revenue
Total revenue	[1]	755	1,944	5,993	5,297
Platform and operations services
Revenue
Total revenue	[1]	212,375	144,522	422,275	291,814
Premiums
Revenue
Total revenue		$ 25,502	$ 45,493	$ 57,649	$ 92,604
[1]	See Note 18 for amounts attributable to related parties included in these line items.

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative transition adjustment	Common StockClass A Common Stock	Common StockClass B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit)Cumulative transition adjustment	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2018			79,172	3,190
Beginning balance at Dec. 31, 2018	$ 1,189,356		$ 792	$ 31	$ 1,093,174	$ (182)	$ 50,009		$ 45,532
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	8,515				8,515
Exercise of stock options (in shares)			104
Exercise of stock options	948		$ 1		947
Restricted stock units vested, net of shares withheld for taxes (in shares)			280
Restricted stock units vested, net of shares withheld for taxes	(2,405)		$ 3		(2,408)
Class A common stock issued for payment of earn-outs (in shares)			43
Class A common stock issued for payment of earn-outs	800				800
Amount attributable to NCI from 2019 business combination	6,500								6,500
Shares issued for equity-method investments and asset acquisitions (in shares)			1,732
Shares issued for equity-method investments and asset acquisitions	23,556		$ 18		23,538
Exchange of Class B common stock (in shares)			2,484	(2,484)
Exchange of Class B common stock			$ 24	$ (24)	33,946				(33,946)
Foreign currency translation adjustment	35					35
Net loss	(80,549)						(78,354)		(2,195)
Reclassification of non-controlling interests	0				(187)				187
Ending balance (in shares) at Jun. 30, 2019			83,815	706
Ending balance at Jun. 30, 2019	$ 1,146,756		$ 838	$ 7	1,158,325	(147)	(28,345)		16,078
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201602Member
Beginning balance (in shares) at Mar. 31, 2019			79,429	3,190
Beginning balance at Mar. 31, 2019	$ 1,150,126		$ 794	$ 31	1,096,089	(158)	3,270		50,100
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	4,362				4,362
Exercise of stock options (in shares)			93
Exercise of stock options	823		$ 1		822
Restricted stock units vested, net of shares withheld for taxes (in shares)			77
Restricted stock units vested, net of shares withheld for taxes	(222)		$ 1		(223)
Shares issued for equity-method investments and asset acquisitions (in shares)			1,732
Shares issued for equity-method investments and asset acquisitions	23,556		$ 18		23,538
Exchange of Class B common stock (in shares)			2,484	(2,484)
Exchange of Class B common stock			$ 24	$ (24)	33,946				(33,946)
Foreign currency translation adjustment	11					11
Net loss	(31,900)						(31,615)		(285)
Reclassification of non-controlling interests					(209)				209
Ending balance (in shares) at Jun. 30, 2019			83,815	706
Ending balance at Jun. 30, 2019	1,146,756		$ 838	$ 7	1,158,325	(147)	(28,345)		16,078
Beginning balance (in shares) at Dec. 31, 2019			84,589	0
Beginning balance at Dec. 31, 2019	929,047	$ (2,970)	$ 846	$ 0	1,173,708	(234)	(251,962)	$ (2,970)	6,689
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	7,211				7,211
Exercise of stock options (in shares)			90
Exercise of stock options	526		$ 1		525
Restricted stock units vested, net of shares withheld for taxes (in shares)			350
Restricted stock units vested, net of shares withheld for taxes	(1,331)		$ 4		(1,335)
Share retirement (in shares)			(188)
Share retirement	(685)		$ (2)		(683)
Class A common stock issued for payment of earn-outs (in shares)			616
Class A common stock issued for payment of earn-outs	4,185		$ 6		4,179
Disposal of assets	(6,689)								(6,689)
Foreign currency translation adjustment	(157)					(157)
Net loss	(282,273)						(282,273)
Reclassification of non-controlling interests									(6,689)
Ending balance (in shares) at Jun. 30, 2020			85,457	0
Ending balance at Jun. 30, 2020	$ 646,864		$ 855	$ 0	1,183,605	(391)	(537,205)		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Beginning balance (in shares) at Mar. 31, 2020			85,450	0
Beginning balance at Mar. 31, 2020	$ 847,072		$ 855	$ 0	1,180,288	(387)	(333,684)		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,703				3,703
Exercise of stock options (in shares)			82
Exercise of stock options	443		$ 1		442
Restricted stock units vested, net of shares withheld for taxes (in shares)			113
Restricted stock units vested, net of shares withheld for taxes	(144)		$ 1		(145)
Share retirement (in shares)			(188)
Share retirement	(685)		$ (2)		(683)
Foreign currency translation adjustment	(4)					(4)
Net loss	(203,521)						(203,521)
Reclassification of non-controlling interests									0
Ending balance (in shares) at Jun. 30, 2020			85,457	0
Ending balance at Jun. 30, 2020	$ 646,864		$ 855	$ 0	$ 1,183,605	$ (391)	$ (537,205)		$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows From (Used In) Operating Activities
Net loss	$ (282,273)	$ (80,549)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Change in fair value of contingent consideration and indemnification asset	(3,062)	200
(Gain) loss on disposal of assets	6,447	(9,600)
(Income) loss from equity method investees	(24,731)	2,328
Depreciation and amortization expenses	31,916	29,558
Goodwill impairment	215,100	0
Equity method investments impairment	47,133	0
Stock-based compensation expense	7,211	9,287
Deferred tax (benefit) provision	(892)	782
Amortization of contract cost assets	10,272	2,773
Amortization of deferred financing costs	6,079	4,600
Interest from customer advance for regulatory capital requirements	(1,316)	0
Other current operating cash inflows (outflows), net	224	527
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net and contract assets	(23,946)	9,891
Prepaid expenses and other current and noncurrent assets	(3,912)	(8,882)
Contract cost assets	(5,503)	(8,110)
Accounts payable	11,690	1,025
Accrued liabilities	4,071	(4,167)
Accrued compensation and employee benefits	(10,118)	1,394
Deferred revenue	(6,400)	6,339
Reserve for claims and performance-based arrangements	33,259	5,457
Right-of-use operating assets	3,620	(25,350)
Operating lease liabilities	1,783	28,041
Other long-term liabilities	473	(4,786)
Net cash and restricted cash from (used in) operating activities	17,125	(39,242)
Cash Flows Used In Investing Activities
Cash paid for asset acquisitions or business combinations	0	(6,000)
Customer advance for regulatory capital requirements	0	(45,400)
Loan for implementation funding	(400)	2,830
Disposal of non-strategic assets	(2,287)	0
Investments in and advances to equity method investees	0	(16,892)
Purchases of investments	(1,447)	(7,122)
Maturities of investments	3,099	0
Investments in internal-use software and purchases of property and equipment	(17,455)	(17,739)
Purchase and maturities of restricted investments	108	(493)
Net cash and restricted cash used in investing activities	(18,382)	(90,816)
Cash Flows (Used In) from Financing Activities
Changes in working capital balances related to claims processing on behalf of partners	26,715	(119,506)
Amount received from escrow in asset acquisition	0	500
Deferred financing costs related to 2025 Notes	0	(608)
Proceeds from stock option exercises	526	948
Taxes withheld and paid for vesting of restricted stock units	(1,331)	(2,405)
Net cash and restricted cash from (used in) financing activities	25,910	(121,071)
Effect of exchange rate on cash and cash equivalents and restricted cash	26	(29)
Net increase (decrease) in cash and cash equivalents and restricted cash	24,679	(251,158)
Cash and cash equivalents and restricted cash as of beginning-of-period	128,531	388,325
Cash and cash equivalents and restricted cash as of end-of-period	$ 153,210	$ 137,167

Organization

Organization	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations as well as health plans to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be integrated clinical and financial responsibility for populations. The Company operates through two segments. The Company’s Services segment (“Services”) includes clinical and administrative solutions designed to help our partners manage and administer patient health in a more cost-effective manner. We have two clinical solutions: (i) total cost of care management and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one type of solution, or multiple types of solutions, depending on specific needs. True Health is our second reportable segment. True Health is a physician-led health plan in New Mexico available through the commercial market for employer-sponsored health coverage and individual market as well as the Federal Employee Health Benefits Program. Since its inception, the Company has incurred losses from operations. As of June 30, 2020, the Company had unrestricted cash and cash equivalents of $98.3 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued. The Company’s headquarters is located in Arlington, Virginia. Evolent Health LLC Governance Our operations are conducted through Evolent Health LLC and subsequent to the offering reorganization at the time of our initial public offering (the “Offering Reorganization”), the financial results of Evolent Health LLC were consolidated in the financial statements of Evolent Health, Inc. Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC’s business and affairs and is responsible for the management of its business. Issuances of Common Units Evolent Health LLC may only issue Class A common units to us, as the sole managing member of Evolent Health LLC. Class B common units may be issued only to persons or entities we permit. Such issuances of Class B common units shall be made in exchange for cash or other consideration. Class B common units may not be transferred as Class B common units except to certain permitted transferees and in accordance with the restrictions on transfer set forth in the third amended and restated operating agreement of Evolent Health LLC. Any such transfer must be accompanied by the transfer of an equal number of shares of our Class B common stock.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle	Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2019, has been derived from audited financial statements as of that date. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2019 Form 10-K. Summary of Significant Accounting Policies Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2019 Form 10-K for a complete summary of our significant accounting policies. Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets (including equity method investments), stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, valuation of intangible assets (including goodwill), purchase price allocation in taxable stock transactions and useful lives of intangible assets. Principles of Consolidation The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Operating Segments Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of two clinical solutions: (i) total cost of care services and (ii) specialty care management services, and one administrative solution: comprehensive health plan administration services. Our True Health segment consists of a commercial health plan we operate in New Mexico that historically focused on small and large businesses. In 2020, True Health diversified its services to offer coverage for individuals and families as well as the Federal Employee Health Benefits Program. See Note 19 for a discussion of our operating results by segment. Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: June 30, 2020 December 31, 2019 Collateral for letters of credit for facility leases (1) $ 3,610 $ 3,610 Collateral with financial institutions (2) 5,745 5,742 Claims processing services (3) 44,886 18,171 Other 1,412 817 Total restricted cash and restricted investments $ 55,653 $ 28,340 Current restricted investments $ 100 $ 704 Current restricted cash 46,794 19,376 Total current restricted cash and restricted investments $ 46,894 $ 20,080 Non-current restricted investments $ 615 $ 113 Non-current restricted cash 8,144 8,147 Total non-current restricted cash and restricted investments $ 8,759 $ 8,260 (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements. As of both June 30, 2020 and December 31, 2019, approximately $1.0 million of the collateral amount was held in a trust account and invested in money market funds related to risk-sharing arrangements. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. As of both June 30, 2020 and December 31, 2019, approximately $4.7 million, of the collateral amounts were held in a FDIC participating bank account. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows. June 30, 2020 2019 Cash and cash equivalents $ 98,272 $ 92,821 Restricted cash and restricted investments 55,653 45,158 Restricted investments included in restricted cash and restricted investments (715) (812) Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 153,210 $ 137,167 Notes Receivable Notes receivable are carried at the face amount of each note plus accrued interest receivable, less received payments. The Company does not typically carry notes receivable in the course of its regular business, but contributed $40.0 million in the form of an advance for regulatory capital requirements (the “Passport Note”) under an agreement that Passport entered into during the second quarter of 2019. The Passport Note carries a fixed interest rate of 6.5% per annum and is required to be repaid, plus accrued interest, in a single payment on July 1, 2025, the maturity date, or earlier, subject to regulatory approval. The Passport Note is required to be repaid out of the surplus in excess of Passport’s obligations to its policyholders, claimant and beneficiary claims and all other creditors. As of June 30, 2020, the outstanding principal balance of the Passport Note was $40.0 million, excluding approximately $2.7 million of accrued interest. Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred. Equity Method Investments For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in and advances to equity method investees on the consolidated balance sheets with income or loss included in loss from equity method investees on the consolidated statements of operations and comprehensive income (loss). Impairment of Equity Method Investments The Company considers certain factors to determine if there is a decrease in its investment value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 15 for additional discussion regarding impairments on equity method investments. Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level, which is consistent with the way management evaluates our business. The Company has four reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during the six months ended June 30, 2020 and the year ended December 31, 2019. Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 4-5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets. Reserves for Claims and Performance-based Arrangements Reserves for performance-based arrangements and claims for our Services and True Health segments reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under a reinsurance agreement for 2019 as discussed further in Note 10. The reinsurance agreement was terminated in December 2019. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 20 for additional discussion regarding our reserves for claims and performance-based arrangements. Leases As discussed in Note 3, we adopted Accounting Standards Update (“ASU”) 2016-02 effective January 1, 2019. The following reflects our updated policy for leases. The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. Refer to Note 11 for additional lease disclosures. Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition for our Services segment from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derived revenue in 2019 from reinsurance premiums assumed from NMHC under the terms of the reinsurance agreement (as defined in Note 10). The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as deferred revenue on our consolidated balance sheets. See Note 5 for further discussion of our policies related to revenue recognition. Foreign Currency The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020 and 2019.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards Adoption of New Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases , in order to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases, including a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02 In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Services Contract . The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted the requirements of ASU 2018-15 effective January 1, 2019. There was no material impact to our consolidated balance sheets or results of operations as of or for the year ended December 31, 2019. In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update). ASU 2019-07 clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. The disclosure and presentation amendments included in ASU 2019-07, which were effective upon issuance of the standard and were to be applied prospectively, did not have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing “incurred loss” framework with an expected credit loss recognition model. The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts. The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of ASU 2016-13 In August 2018, the FASB issued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement . ASU 2018-13 amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosures. This ASU is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. We adopted the requirements of this standard effective January 1, 2020 and determined it did not have a material impact on our consolidated financial statements and related disclosures.

Transactions

Transactions	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Transactions	Transactions Equity Investments Passport On December 30, 2019, Passport, Passport Health Solutions, LLC, a Kentucky nonprofit limited liability company and subsidiary of Passport (“PHS I”), the Company and Justify Holdings, Inc., a Kentucky corporation and a previous subsidiary of the Company (the “Passport Buyer”), closed a transaction whereby Passport Buyer acquired substantially all of the assets and assumed substantially all of the liabilities of Passport and PHS I for $70.0 million in cash and issued a 30% equity interest in the Passport Buyer to the following provider sponsors of Passport: the University of Louisville, the University of Louisville Physicians, the University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the “Sponsors”). As of December 30, 2019, Justify Holdings, Inc. became Passport Health Plan, Inc. $16.2 million of the cash consideration was placed in escrow until such time as PHS I delivers to the Passport Buyer certain owned real property and improvements. During the three months ended June 30, 2020, the Passport Buyer did not meet certain statutory capital thresholds as a result of the owned real property and improvements not being transferred and $16.2 million was released from escrow and returned to the Passport Buyer. If the transfer of owned real property and improvements does not occur by December 31, 2020, then Passport Buyer and PHS I will mutually agree to dispose and/or transfer the owned real property and improvements. The Company accounts for its investment in Passport under the equity method of accounting because while it has significant influence over Passport, it shares control over the activities of Passport that most significantly impact Passport’s economic performance. These activities include approval of material provider network additions or deletions and material agreements. Decisions on material providers are assessed frequently by Passport as a key measure in assessing the plan’s current financial Performance as medical costs account for a majority of total plan costs. Accordingly, the approval of the material provider network additions or deletions is deemed an activity that significantly impacts Passport’s operating and financial performance. In addition, we analyzed the Passport transaction to determine if the Company is the primary beneficiary of a variable interest entity (a “VIE”). We considered both the power to direct the activities that most significantly impact the economic performance of the VIE and a variable interest that could potentially be significant to the VIE. The Company determined that its interest in this entity meets the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities that most significantly impact Passport’s performance. Therefore, the Company did not consolidate the VIE. Passport is currently one of five Medicaid-managed care organizations serving the Commonwealth of Kentucky. Passport’s current contract to provide managed care for Medicaid expires on December 31, 2020. In 2019, Passport submitted a proposal to continue providing managed care for Medicaid in the Commonwealth of Kentucky through December 31, 2024 in response to the ongoing “request for proposal” process (the “RFP”) of the CHFS. While Passport was not initially awarded a Kentucky managed Medicaid contract for the next contract period, the bidding process was reopened, and a revised proposal was submitted during the first quarter of 2020. During May 2020, the CHFS announced that Passport was not awarded a Kentucky managed care Medicaid contract for the next contract period. As a result, we do not expect to receive any material revenue under our management services agreement from Passport Buyer subsequent to December 31, 2020. However, we expect to recover substantially all the value of our investment in Passport. In addition, since Passport was not awarded a new Medicaid contract with CHFS, the Company is required to acquire the Sponsors’ 30% ownership interest in Passport Buyer for $20.0 million within twelve months following December 31, 2020, the expiration of Passport’s current Medicaid contract. On June 18, 2019, we contributed the Passport Note under an agreement with Passport. The Passport Note carries a fixed interest rate of 6.5% per annum and is required to be repaid, plus accrued interest, in a single payment on July 1, 2025, the maturity date, or earlier, subject to regulatory approval. The Passport Note is required to be repaid out of surplus in excess of Passport’s obligations to its policyholders, claimant and beneficiary claims and all other creditors. Additionally, on June 6, 2019, the Company and Passport entered into an Indemnity Agreement (the “Indemnity Agreement”), with an insurance company (the “Surety”). The Surety issued a performance bond in the amount of $25.0 million to secure Passport’s performance under its Medicaid contract with the Kentucky Cabinet of Health and Family Services (“CHFS”). Pursuant to the Indemnity Agreement, the Company and Passport are jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond’s original expiry date was June 30, 2020. During the three months ended June 30, 2020, the expiry date was extended to the end of Passport’s current Medicaid contract on December 31, 2020. In connection with the consummation of the transactions, the Sponsors, the Passport Buyer and a subsidiary of the Company entered into a shareholders’ agreement that provides for the governance of the Passport Buyer following the closing, and certain other rights between the parties thereto. The shareholders agreement provides that written consent of majority holders is required for certain significant governance and operational matters, including the appointment, removal or replacement of the Passport Buyer’s chief executive officer, material changes to the provider network and other significant matters. Loss on Disposal of Assets During 2019, the Company, through a consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary and recorded a loss on disposal of assets of $6.4 million. The Company did not have any continuing involvement with the subsidiary after the consummation of this transaction.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation Services Revenue Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan strategy. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Platform and Operations Services Revenue Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our clinical solutions are designed to lower the medical expenses of our partners and include our total cost of care, population health and specialty care management services; our administrative solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services. Contracts to provide these services may be developed on an integrated basis. For purposes of revenue disaggregation, we classify contracts including both clinical and administrative solutions into the category corresponding to the majority of services provided under those contracts. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement. Disaggregation of Revenue The following table represents Evolent’s Services segment revenue disaggregated by type of services (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance . For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Services Revenue Transformation services $ 755 $ 1,944 $ 5,993 $ 5,297 Platform and operations services Clinical solutions 161,774 94,573 321,582 191,204 Administrative solutions 50,562 49,058 100,616 99,683 Transaction Price Allocated to the Remaining Performance Obligations For contracts with a term greater than one year, we have allocated approximately $108.2 million of transaction price to performance obligations that are unsatisfied as of June 30, 2020. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 33% and 69% of these remaining performance obligations by December 31, 2020, and December 31, 2021, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected. Contract Balances Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within contract assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets. Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets, and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets. The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): June 30, 2020 December 31, 2019 Short-term receivables (1) $ 93,066 $ 71,707 Long-term receivables (1) 740 709 Short-term contract assets 2,346 1,751 Long-term contract assets 47 999 Short-term deferred revenue 13,247 19,828 Long-term deferred revenue 1,338 1,330 (1) Excludes pharmacy claims receivable and premiums receivable Changes in contract assets and deferred revenue for the six months ended June 30, 2020, are as follows (in thousands): For the Six Months Ended June 30, 2020 Contract assets Balance as of beginning-of-period $ 2,750 Reclassification to receivables, as the right to consideration becomes unconditional (1,477) Contract assets recognized, net of reclassification to receivables 1,120 Balance as of end-of-period $ 2,393 Deferred revenue Balance as of beginning-of-period $ 21,158 Reclassification to revenue, as a result of performance obligations satisfied (15,538) Cash received in advance of satisfaction of performance obligations 8,965 Balance as of end-of-period $ 14,585 The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in previous period was $6.5 million and $7.7 million during the three and six months ended June 30, 2020, due primarily to net gain share as well as changes in other estimates. Contract Cost Assets Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June 30, 2020 and December 31, 2019, the Company had $4.0 million and $4.7 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortiza tion expense of $0.4 million and $0.9 million for the three and six months ended June 30, 2020, respectively, and $0.1 million and $0.2 million for the three and six months ended June 30, 2019. In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of June 30, 2020 and December 31, 2019, the Company had $27.7 million and $31.8 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $4.3 million and $9.4 million for the three and six months ended June 30, 2020, respectively, and $1.4 million and $2.6 million for the three and six months ended June 30, 2019. These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.

Credit Losses

Credit Losses	6 Months Ended
	Jun. 30, 2020
Credit Loss [Abstract]
Credit Losses	Credit Losses We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advance for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers’ and other third parties’ ability to pay. We did not observe notable increases in delinquencies during the three and six month periods ended June 30, 2020. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six month periods ended June 30, 2020. Accounts Receivable from Revenue Transactions Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company’s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company’s consolidated balance sheets. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals, and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts. Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets at June 30, 2020, 59% were current, 28% were past due less than 60 days, with 40% past due less than 120 days. At June 30, 2020, we reported $104.4 million of accounts receivable, certain non-trade accounts receivable included in prepaids and other assets on the consolidated balance sheet and contract assets, net of allowances of $1.5 million. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2020 (in thousands): For the Six Months Ended June 30, 2020 Balance as of December 31, 2019 $ (41) Cumulative transition adjustment (2,815) Provision for credit losses (260) Charge-offs 1,575 Balance as of June 30, 2020 $ (1,541) Investments Held at Amortized Cost In January 2018, Evolent acquired certain assets from New Mexico Health Connections, including a commercial plan and health plan management services organization. The acquired assets were contributed to a new entity, True Health, which is a wholly-owned subsidiary of Evolent. True Health invests in certain debt securities which are classified as held-to-maturity in Evolent’s consolidated financial statements because True Health, as Evolent’s wholly-owned subsidiary, has the intent and ability to hold the securities until their individual maturities. True Health invests in debt securities pursuant to an investment policy governing the nature and type of investments based on the Company’s business strategy, risk tolerance, and investment objectives. The amortized cost of our investments as of June 30, 2020 and December 31, 2019 (in thousands) and interest income for the three and six months ended June 30, 2020 were as follows: Amortized Cost Interest Income for the Three Months Ended June 30, Interest Income for the Six Months Ended June 30, June 30, 2020 December 31, 2019 2020 2019 2020 2019 U.S. Treasury bills $ 8,909 $ 10,784 $ 57 $ 61 $ 122 $ 119 Corporate bonds 1,706 1,705 14 11 29 20 Collateralized mortgage obligations 5,695 5,472 51 17 104 29 Yankees 597 597 6 6 11 11 Total investments $ 16,907 $ 18,558 $ 128 $ 95 $ 266 $ 179 The Company reviewed its held-to-maturity investments to determine which types of securities have zero risk of credit loss because payments are guaranteed by a third party. Based on this analysis, the Company determined that the expected credit losses on U.S. Treasury bills and mortgage backed securities from government sponsored enterprise (“GSE”) is zero. The expected credit losses on non-GSE backed securities is considered immaterial. As of June 30, 2020, all of the Company’s held-to-maturity investments were rated investment-grade or better and all payments of interest or principal are current. Customer Advance for Regulatory Capital and Notes Receivable Customer Advance for Regulatory Capital On June 18, 2019, we contributed the Passport Note under an agreement with Passport. The Passport Note carries a fixed interest rate of 6.5% per annum and is required to be repaid, plus accrued interest, in a single payment on July 1, 2025, the maturity date, or earlier, subject to regulatory approval. The Passport Note is required to be repaid out of surplus in excess of Passport’s obligations to its policyholders, claimant and beneficiary claims and all other creditors. The company recorded the Passport Note at amortized cost basis, including accrued interest of $2.7 million, on the consolidated balance sheets and reports principal in customer advance for regulatory capital requirements, net of allowances and accrued interest in prepaid expenses and other non-current assets, net. The Passport Note is subject to a minimum risk-based-capital percentage of 150% and as such, if Passport maintains or exceeds the minimum risk-based-capital percentage, the Company believes Passport has sufficient liquidity to repay all outstanding loan principal and accrued interest. Evolent evaluated this note and employed a probability of default and loss given default framework which relies on contractual cash flows to determine the exposure at default at any point in the future. The model calculates contractual cash flows for all remaining periods of the note’s contractual life based on terms of the notes and utilize the amortization principles set forth within those terms under the assumption that the note will behave as expected under the contract. Forecasted probability of default rates and loss given default rates are applied in each future contractual period to determine the period-specific amount of default and the associated loss given that default has occurred. Forward looking probability of default and loss given default rates are forecasted using regression-based econometric techniques. Using reasonable and supportable forecasts of relevant macroeconomic conditions, Evolent forecasts expected future risk-based-capital percentages. Evolent utilizes these forecasted risk-based-capital percentages to derive the future probability of default and loss given default rates applied to the future period-specific exposure at default, as calculated based upon contractual loan terms, to derive an excepted loss estimate. While macroeconomic conditions have deteriorated as of June 30, 2020 compared to December 31, 2019, we determined the changes in economic conditions did not have a material impact on the performance of the Passport Note because there is sufficient risk-based-capital to repay all principal and accrued interest. At June 30, 2020, we reported $40.0 million of customer advances for regulatory capital, net of allowances of $45 thousand. Principal and all accrued interest is due at maturity of the note on July 1, 2025. While the Company is currently accruing interest on the Passport Note, it may stop accruing interest in the future if the Passport Note borrower is in default of either principal or interest payments. Notes Receivable On September 30, 2019, we entered into an amended agreement with an equity method investee to reduce our maximum funding for operations to $5.0 million (the “Note”) through a line of credit. The Note carries a fixed interest rate of 6.5% per annum and is required to be repaid, plus accrued interest, in monthly payments on April 30, 2019 through the note end date of April 1, 2030. As of June 30, 2020 and December 31, 2019, the equity method investee had drawn $1.4 million and $1.0 million under this Note, respectively. The Company recorded the Note at amortized cost basis, including accrued interest, on the consolidated balance sheets and reports principal in prepaid expenses and other non-current assets, net and accrued interest in prepaid expenses and other current assets, net. The remaining undrawn amount is an off-balance sheet credit commitment which is subject to measurement because the Company does not have the ability to rescind its commitment to extend this credit unconditionally. The allowance associated with the undrawn amounts is recorded in other long-term liabilities on the consolidated balance sheets and will be reclassified from other long-term liabilities to prepaid expenses and other non-current assets on the consolidated balance sheets as the Note is drawn. Evolent evaluated this note and employed a probability of default and loss given default framework which relies on contractual cash flows to determine the exposure at default at any point in the future. The model calculates contractual cash flows for all remaining periods of the note’s contractual life based on terms of the notes and utilize the amortization principles set forth within those terms under the assumption that the note will behave as expected under the contract. Forecasted probability of default rates and loss given default rates are applied in each future contractual period to determine the period-specific amount of default and the associated loss given that default has occurred. The probability of default assumption relies upon a set maximum period-specific rate which is derived based upon historical peer-institution loss experience. The loss given default rate for the Note is assumed to be 50% in every period. This assumption relies upon a 50/50 expectation of a good outcome versus a bad outcome given a default event’s occurrence. Under a good outcome, the Company would achieve a 100% recovery of the defaulted balance whereas under a bad outcome the Company would recover 0% of the defaulted balance. At June 30, 2020, we reported $1.4 million of notes receivable, net of allowances on drawn principal of $14 thousand in prepaid expenses and other non-current assets and allowances on undrawn principal of $37 thousand in other long-term liabilities on the consolidated balance sheets. In addition, as of January 1, 2020 and June 30, 2020, the Note is current on its payments of principal and interest, however the Florida Agency for Healthcare Administration (the “Agency”) reviews requests for payments on a quarterly basis and will only approve the requests when it is satisfied that any repayment will not be reasonably likely to cause the borrower to be unable to meet its insolvency or surplus requirements. Circumstances under which the Agency will approve repayment include, but are not limited to, when the Premium to Surplus ratio is 10 to 1 or below. While the Company is currently accruing interest on the Note, it may stop accruing interest in the future if the Note borrower is in default of either principal or interest payments.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net The following summarizes our property and equipment (in thousands): June 30, 2020 December 31, 2019 Computer hardware $ 12,061 $ 11,604 Furniture and equipment 3,588 3,649 Internal-use software development costs 126,203 112,501 Leasehold improvements 15,537 12,415 Total property and equipment 157,389 140,169 Accumulated depreciation and amortization expenses (68,834) (55,014) Total property and equipment, net $ 88,555 $ 85,155 The Company capitalized $6.4 million and $13.7 million of internal-use software development costs for the three and six months ended June 30, 2020, respectively and $8.2 million and $16.9 million for the three and six months ended June 30, 2019, respectively. The net book value of capitalized internal-use software development costs was $77.1 million and $74.9 million as of June 30, 2020 and December 31, 2019, respectively. Depreciation expense related to property and equipment was $7.1 million and $13.9 million for the three and six months ended June 30, 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.0 million and $11.6 million, respectively. Depreciation expense related to property and equipment was $5.7 million and $10.9 million

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net Goodwill Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company has four reporting units. Our reporting units are not discrete legal entities with discrete full financial statements. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a goodwill impairment analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. Our annual goodwill impairment review occurs during the fourth quarter of each fiscal year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation. 2019 Goodwill Impairment Test During the second half of 2019, the price of our Class A common stock declined significantly. The average closing price per share of our Class A common stock for the period from May 1 to October 31 decreased by $6.59 per common share, or 43.5%, compared to the average closing price for the period from January 1 to April 30. In addition, it was not certain that Passport would be awarded a Kentucky managed Medicaid contract for the next contract period, which was expected to begin on January 1, 2021. Since Passport was not awarded a contract under the RFP, we expect that we will not receive any material revenue under our management services agreement from Passport Buyer subsequent to December 31, 2020 and the value of our investment in Passport and goodwill will be negatively impacted. The non-renewal of Passport’s contract would reduce our medium-term and long-term cash flow projections for one of our reporting units, causing the decline in our stock price to possibly be further prolonged, indicating it is more likely than not that that the fair value of the reporting units is less than the reporting unit’s carrying amounts, triggering an interim quantitative assessment. In performing our October 31, 2019 impairment test, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (“income approach”). In determining the estimated fair value using the income approach, we projected future cash flows based on management’s estimates and long-term plans and applied a discount rate based on the Company’s weighted average cost of capital. This analysis required us to make judgments, including about revenues, expenses, fixed asset and working capital requirements, the timing of exchanges of our Class B common shares, capital market assumptions, cash flows, the probability of the Passport RFP outcome and discount rates. The fair values determined by the income approach, as described above, were weighted considering future resolution of the Passport RFP result to determine the concluded fair value for each reporting unit. If the probability of Passport being awarded a contract under the RFP increases, it is unlikely to result in a future impairment charge ignoring other events or circumstances, however, if the probability of Passport being awarded a contract under the RFP decreases, we will likely have a future impairment charge. As of October 31, 2019, we determined that one of our three reporting units in the Services segment had an estimated fair value less than its carrying value. As a result, we recorded a non-cash goodwill impairment charge of $199.8 million in goodwill impairment on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2019. If other indications of impairment exist we may be required to recognize additional impairments in the future as a result of market conditions or other factors related to our performance, including changes in our forecasted results, investment strategy, interest rates or assumptions used as part of the goodwill impairment analysis. Any further impairment charges that we may record in the future could be material to our results of operations. 2020 Goodwill Impairment Analysis As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit’s carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company’s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. As of March 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge for the year ended December 31, 2019 was $431.7 million. During May 2020, the CHFS announced that Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and its Medicaid contract with the CHFS will expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its annual goodwill impairment test that would indicate it was more likely than not that the fair value of one of its three reporting units in the Services segment was less than the reporting unit’s carrying amounts. In performing our interim goodwill impairment analysis, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (“income approach”). In determining the estimated fair value, we projected future cash flows based on management’s estimates and long-term plans and applied a discount rate based on the Company’s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value. As a result, we recorded a non-cash goodwill impairment charge of $215.1 million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. As of June 30, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge for the three and six months ended June 30, 2020 was $214.3 million. The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): For the Six Months Ended June 30, 2020 Services True Health Consolidated Balance as of December 31, 2019 (1) $ 566,359 $ 5,705 $ 572,064 Goodwill disposal (2) (2,200) — (2,200) Impairment (215,100) — (215,100) Foreign currency translation (69) — (69) Balance as of June 30, 2020 $ 348,990 $ 5,705 $ 354,695 For the Year Ended December 31, 2019 Services True Health Consolidated Balance as of December 31, 2018 (1) $ 762,419 $ 5,705 $ 768,124 Goodwill acquired 3,416 — 3,416 Measurement period adjustments 351 — 351 Impairment (199,800) — (199,800) Foreign currency translation (27) — (27) Balance as of December 31, 2019 $ 566,359 $ 5,705 $ 572,064 (1) Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of June 30, 2020 and December 31, 2019, respectively. (2) Goodwill written down on disposal of a consolidated subsidiary. Intangible Assets, Net Details of our intangible assets (in thousands) are presented below: June 30, 2020 December 31, 2019 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 13.7 $ 23,300 $ 5,581 $ 17,719 14.2 $ 23,300 $ 4,891 $ 18,409 Customer relationships 16.6 281,219 50,988 230,231 16.8 291,519 44,750 246,769 Technology 2.3 82,922 58,204 24,718 2.0 82,922 49,760 33,162 Below market lease, net 2.8 1,118 548 570 2.2 2,048 1,334 714 Provider network contracts 3.3 14,475 4,800 9,675 3.7 12,725 3,320 9,405 Total intangible assets, net $ 403,034 $ 120,121 $ 282,913 $ 412,514 $ 104,055 $ 308,459 Amortization expense related to intangible assets was $8.7 million and $18.0 million for the three and six months ended June 30, 2020, respectively. Amortization expense related to intangible assets was $9.6 million and $18.7 million, for the three and six months ended June 30, 2019, respectively. Future estimated amortization of intangible assets (in thousands) as of June 30, 2020, is as follows: 2020 $ 14,842 2021 28,701 2022 24,819 2023 22,055 2024 16,171 Thereafter 176,325 Total future amortization of intangible assets $ 282,913 Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets’ carrying value. We did not identify any circumstances during three months ended June 30, 2020, that would require an impairment test for our intangible assets.

Long-term Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt Credit Agreement On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the “Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the “Initial Term Loan Facility”) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the “DDTL Facility” and, together with the Initial Term Loan Facility, the “Senior Credit Facilities”), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities are guaranteed by the Company and the Company’s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities are secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. The proceeds of the Initial Term Loan were used to finance the Passport transaction and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility may be used, subject to the Company’s satisfaction of specified conditions, to finance the repayment or repurchase of the Company’s 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. The Initial Term Loan and any loans under the DDTL Facility will mature on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions are satisfied (the foregoing, the “Maturity Date”). The interest rate for each loan under the Senior Credit Facilities is calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum is payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. The Company recorded $2.0 million and $4.0 million in interest expense related to our Credit Agreement for the three and six months ended June 30, 2020. Amounts outstanding under the Senior Credit Facilities may be prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (2) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (3) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction. The Senior Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $4.7 million of debt issuance costs in connection with this Credit Agreement, which will be included in long-term debt, net of discount on our consolidated balance sheets and will be amortized into interest expense over the life of the agreement. For the three and six months ended June 30, 2020, the Company recorded $0.5 million and $1.1 million in interest expense related to the amortization of the debt discount and the issuance costs. The Company was in compliance with all applicable covenants as of June 30, 2020. Warrant Agreement In conjunction with the Company’s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders can exercise the warrants at any time until thirty days after the maturity of the Credit Agreement. The Company, at its sole discretion, can elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares. 2025 Notes In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018, and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018, pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes. Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019, at a rate equal to 1.50% per annum. The Company recorded interest expense of $0.7 million and $1.3 million related to the 2025 Notes for the three and six months ended June 30, 2020 and 2019. The 2025 Notes will mature on October 15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate. The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the three and six months ended June 30, 2020, the Company recorded $2.1 million and $4.3 million, respectively, and $2.1 million and $4.1 million for the three and six months ended June 30, 2019, respectively, of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component. Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. 2021 Notes In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the “2021 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016. Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes will mature on December 1, 2021, unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase all or part of their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental repurchase date. Upon maturity the principal amount of the notes may be settled via shares of the Company’s Class A common stock. We recorded interest expense of $0.6 million and $1.2 million and non-cash interest expense related to the amortization of deferred financing costs of $0.3 million and $0.5 million for each of the three and six months ended June 30, 2020 and 2019, respectively. The 2021 Notes are convertible into shares of the Company’s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $24.03 per share of the Company’s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture). The conversion rate may be adjusted under certain circumstances. The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date. Convertible Senior Notes Carrying Value The 2025 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values of $111.7 million and $123.7 million, respectively, as of June 30, 2020. However, the 2025 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values were $113.6 million and $109.7 million, respectively, based on traded prices on July 2, 2020 and July 1, 2020, respectively, which are Level 2 inputs. As of December 31, 2019, the estimated fair value of the 2025 and 2021 Notes were $122.0 million and $111.3 million, respectively, based on a traded price on December 31, 2019 and December 11, 2019, respectively, which are Level 2 inputs. The 2025 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt (in thousands): June 30, 2020 December 31, 2019 2025 Notes Carrying value $ 111,665 $ 107,169 Unamortized debt discount and issuance costs allocated to debt 60,835 65,331 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 5.3 5.8 2021 Notes Carrying value $ 123,697 $ 123,237 Unamortized issuance costs 1,303 1,763 Principal amount $ 125,000 $ 125,000 Remaining amortization period (years) 1.4 1.9

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Commitments to Equity-Method Investees The Company has contractual arrangements with certain equity-method investees that will require the Company to provide operating capital and reserve support in the form of debt financing of up to $3.6 million and $4.0 million as of June 30, 2020 and December 31, 2019, respectively, in accordance with the Company’s contribution agreements with certain equity-method investees. These obligations are outside of the Company’s control and payment could be requested during 2020. During May 2020, the CHFS announced that Passport was not awarded a Kentucky managed Medicaid contract for the next contract period. As a result, the Company is required to acquire the Sponsors’ 30% ownership interest in Passport Buyer for $20.0 million within twelve months following December 31, 2020, the expiration of Passport’s current Medicaid contract. Refer to Note 4 for additional information about the investment in Passport. Letter of Credit During the third quarter of 2019, the Company established an irrevocable standby letter of credit with a bank for $1.8 million for the benefit of a regulatory authority and, as such, held $1.8 million in restricted cash and restricted investments as collateral as of both June 30, 2020 and December 31, 2019, respectively. The letter of credit expired on December 31, 2019 and was automatically extended without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date, unless the bank elects not to extend beyond the initial or any extended expiry date. Indemnifications The Company’s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements. During the second quarter of 2019, the Company and Passport, a current customer (collectively the “Indemnitors”), pursuant to a state requirement of all participating Medicaid Managed Care Organizations, entered into the Indemnity Agreement with the Surety. The Surety issued a performance bond in the amount of $25.0 million to secure the customer’s performance under a contract to provide Medicaid Managed Care Services for the benefit of a third party (the “Beneficiary”). Pursuant to the Indemnity Agreement, the Indemnitors are jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond’s effective date is July 1, 2019, and original expiry date was June 30, 2020. During the three months ended June 30, 2020, the expiry date was extended to the end of the current Medicaid contract on December 31, 2020. To date, the Company has not incurred any material costs as a result of the Indemnity Agreement and has not accrued any liabilities related to it in the accompanying consolidated financial statements. Pre-IPO Investor Registration Rights Agreement We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016. We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders for the three and six months ended June 30, 2020. Momentum Registration Rights Agreement On May 24, 2019, in connection with the GlobalHealth transaction, the Company entered into a registration rights agreement with Momentum Health Holdings, LLC (“MHG”), which granted certain registration rights to MHG as a holder of shares of the Company’s Class A common stock. Pursuant to our contractual obligations under this agreement, we filed a resale prospectus supplement in respect of the registrable shares on May 28, 2019. The Company will pay certain costs and expenses, other than any underwriting discounts and commissions, in connection with the relevant resale registration statement. We did not incur any material expenses related to the resale registration statement during the three and six months ended June 30, 2020. Guarantees As part of our strategy to support certain of our partners in the Next Generation Accountable Care Program, we entered into upside and downside risk-sharing arrangements. Our downside risk-sharing arrangements are limited to our fees and are executed through our wholly-owned captive insurance company. To satisfy the capital requirements of our captive insurance entity as well as state insurance regulators, the Company entered into letters of credit of $5.7 million as of both June 30, 2020 and December 31, 2019, respectively, to secure potential losses related to insurance services. These amounts are in excess of our actuarial assessment of loss. During the three and six months ended June 30, 2020, the Company entered into a guarantee agreement whereby it agreed to provide support on behalf of Passport Buyer to maintain a minimum risk-based-capital of 150% with the Kentucky Department of Insurance. The maximum exposure is limited to amounts funded to return Passport Buyer to a risk-based-capital of 150%, however as of June 30, 2020, no amounts have been funded under this guarantee. Reinsurance Agreements During the fourth quarter of 2017, the Company entered into a $10.0 million capital-only reinsurance agreement with NMHC which expired on December 31, 2018. The purpose of the capital-only reinsurance was to provide balance sheet support to NMHC. There was no uncertainty to the outcome of the agreement as there was no transfer of underwriting risk to Evolent or True Health, and neither Evolent nor True Health was at risk for any cash payments on behalf of NMHC. As a result, this agreement did not qualify for reinsurance accounting. During the fourth quarter of 2018, the Company terminated its prior reinsurance agreement with NMHC and entered into a 15-month quota-share reinsurance agreement with NMHC. Under the terms of the new reinsurance agreement, NMHC ceded 90% of its gross premiums to the Company and the Company indemnified NMHC for 90% of its claims liability. The maximum amount of exposure to the Company was capped at 105% of premiums ceded to the Company by NMHC. The new reinsurance agreement qualified for reinsurance accounting due to the deemed risk transfer and, as such, the Company recorded the full amount of the gross reinsurance premiums and claims assumed by the Company within premiums and claims expenses, respectively, and recorded claims-related administrative expenses within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) from the legal effective date of the Reinsurance Agreement. Amounts owed to NMHC under the reinsurance agreement are recorded within reserves for claims and performance-based arrangements on our consolidated balance sheets. Amounts owed by NMHC under the reinsurance agreement are recorded within accounts receivable, net on our consolidated balance sheets. During the third quarter of 2019, the Company terminated the new reinsurance agreement with NMHC effective in the fourth quarter of 2019, approximately one and a half months prior to its scheduled end. The following summarizes premiums and claims assumed under the Reinsurance Agreement (in thousands): For the Six Months Ended June 30, 2020 2019 Reinsurance premiums assumed $ — $ 48,828 Claims assumed — 41,424 Claims-related administrative expenses — 8,219 Decrease in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement — 815 Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period — 1,243 Reinsurance payments — 1,235 Receivables for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period $ — $ 823 UPMC Reseller Agreement The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers. Contingencies Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company’s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA. Litigation Matters On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020. The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer, and Steven Wigginton, alleges that the Company’s executives made false or misleading statements regarding its business with Passport. A second amended complaint, which was substantially similar to the amended complaint, was filed on June 8, 2020. The Company filed a motion to dismiss in response on June 22, 2020 and the briefing was completed on July 17, 2020; the parties are now waiting for the court’s decision. Under the Private Securities Litigation Reform Act, PSLRA, all discovery in the case is stayed until the motion to dismiss is decided upon by the court. Based on the Company’s investigation so far, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain, and at this early stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit. The Company is not aware of any other legal proceedings or claims as of June 30, 2020, that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company’s financial position or result of operations. Credit and Concentration Risk The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June 30, 2020, approximately 95.8% of our $153.2 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks, approximately 3.8% were held in money market funds and 0.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date. The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partner included in our Services segment who represented at least 10.0% of our consolidated trade accounts receivable for the periods presented: June 30, 2020 December 31, 2019 Cook County Health and Hospitals System 56.7 % 48.4 % In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners. The following table summarizes those customers of our Services segment who represented at least 10.0% of our consolidated revenue for the periods presented: For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Passport 25.2 % 13.2 % 23.6 % 13.1 % New Mexico Health Connections * 13.2 % * 13.6 % Cook County Health and Hospitals Systems 19.9 % * 19.3 % * * Represents less than 10.0% of the respective balance

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	LeasesThe Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is offset against rent expense over the terms of the respective leases. The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company’s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. In connection with various lease agreements, the Company is required to maintain $3.6 million in letters of credit. As of June 30, 2020 and December 31, 2019, the Company held $3.6 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively. The following table summarizes our primary office leases as of June 30, 2020 (in thousands): Location Lease Termination Term (in years) Future Minimum Lease Commitments Letter of Credit Amount Required Arlington, VA 11.6 $ 40,203 $ 1,579 Riverside, IL 10.8 46,053 232 Louisville, KY (1) 0.5 — — Pune, India 3.3 2,667 — Brea, CA 1.9 2,093 — (1) Lease payments of $4.1 million for Louisville, KY have been prepaid as of June 30, 2020. The following table summarizes the components of our lease cost (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost $ 3,586 $ 3,838 $ 6,642 $ 7,119 Amortization of right-of-use assets 150 — 299 — Interest expense 1 — 3 — Variable lease cost 1,465 1,121 2,517 2,576 Total lease cost $ 5,202 $ 4,959 $ 9,461 $ 9,695 Maturity of lease liabilities (in thousands) as of June 30, 2020, is as follows: Operating lease expense (1) 2020 6,039 2021 11,726 2022 9,801 2023 9,376 2024 8,833 Thereafter 56,093 Total lease payments 101,868 Less: Interest 27,419 Present value of lease liabilities $ 74,449 (1) We have additional operating lease agreements for office space that have not yet commenced as of June 30, 2020. The minimum lease payments for those leases are $0.2 million and the leases will commence during 2020. Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows: June 30, 2020 Weighted average discount rate 6.43 % Weighted average remaining lease term 9.6

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Net loss $ (203,521) $ (31,900) $ (282,273) $ (80,549) Less: Net loss attributable to non-controlling interests — (285) — (2,195) Net loss available for common shareholders - basic and diluted (1) $ (203,521) $ (31,615) $ (282,273) $ (78,354) Weighted-average common shares outstanding - basic and diluted (1) 85,349 82,289 84,977 80,820 Loss per common share Basic and diluted $ (2.38) $ (0.38) $ (3.32) $ (0.97) (1) Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. As holders exchange their Class B common shares for Class A common shares, our interest in Evolent Health LLC will increase. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share. Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below: For the Three Months Ended June 30, 2020 For the Six Months Ended June 30, 2020 2019 2020 2019 Exchangeable Class B common stock — 1,080 — 2,129 Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs") 554 985 376 1,014 Stock options 711 1,495 841 1,729 Convertible senior notes 10,361 10,361 10,361 10,361 Total 11,626 13,921 11,578 15,233

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Award Type Stock options $ 638 $ 903 $ 1,388 $ 2,263 Performance-based stock options — 112 75 222 RSUs 2,006 2,630 3,862 5,060 Performance-based RSUs — 388 — 772 LSUs 1,059 717 1,886 970 Total compensation expense by award type $ 3,703 $ 4,750 $ 7,211 $ 9,287 Line Item Cost of revenue $ 526 $ 891 $ 918 $ 1,682 Selling, general and administrative expenses 3,177 3,859 6,293 7,605 Total compensation expense by financial statement line item $ 3,703 $ 4,750 $ 7,211 $ 9,287 No stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2020 and 2019. Stock-based awards were granted as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Stock options — 18 — 399 RSUs 164 17 1,140 518 LSUs 140 — 520 720

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year. An income tax (benefit) expense of $(3.9) million and $1.4 million was recognized for the three months ended June 30, 2020 and 2019 respectively, which resulted in effective tax rates of 1.9% and (4.6)%, respectively. An income tax (benefit) expense of $(3.6) million and $0.9 million was recognized for the six months ended June 30, 2020 and 2019 respectively, which resulted in effective tax rates of 1.3% and (1.1)%, respectively. On March 27, 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was signed into law. The CARES Act allows net operating losses (“NOLs”) incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years and generate a refund of previously paid federal income taxes. The income tax benefit the Company recorded during the three and six months ended June 30, 2020 primarily relates to the reversal of valuation allowance of $2.3 million of deferred tax asset, which was realized when the Company decided during the second quarter of 2020 to carry back New Century Health’s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. In addition, the Company recognized $1.4 million in income tax benefit due to the difference between the federal tax rate utilized to measure such deferred tax asset and the federal tax rate applicable to the income in the years to which the NOL was carried back. As a result of the NOL carryback, the Company estimates that it will incur additional 2019 income taxes and therefore recognized $0.6 million of income tax expense. The income tax provisions included in the CARES Act, apart from the aforementioned NOL carryback, did not have a material impact on the Company for the three and six months ended June 30, 2020. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax asset, with the exception of a limited amount of indefinite-lived deferred tax assets for which a limited amount of indefinite-lived deferred tax liability provides a source of income. The indefinite-lived deferred tax liability was reduced during the second quarter as a result of the goodwill impairment and the Company recognized a corresponding income tax benefit of $0.8 million. As of December 31, 2019, the Company had unrecognized tax benefits of $0.8 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June 30, 2020, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 10 above and “Part II - Item 8. Financial Statements and Supplementary Data - Note 13” in our 2019 Form 10-K for discussion of our TRA.

Investments In and Advances to

Investments In and Advances to Equity Method Investees	6 Months Ended
	Jun. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investments In and Advances to Equity Method Investees	Investments In and Advances to Equity Method Investees The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs below. As of June 30, 2020 and December 31, 2019, the Company’s economic interests in its equity method investments ranged between 4% and 70%, and voting interests in its equity method investments ranged between 25% and 57%. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities’ earnings and losses for each reporting period. The Company’s proportional share of the gains (losses) from these investments was approximately $25.1 million and $24.7 million for the three and six months ended June 30, 2020, respectively, and $(1.9) million and $(2.3) million for the three and six months ended June 30, 2019, respectively. The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements for the three and six months ended June 30, 2020 was $71.4 million and $131.3 million, respectively, and $11.0 million and $18.1 million for the three and six months ended June 30, 2019, respectively. Unconsolidated VIEs Passport On December 30, 2019, we completed the acquisition of approximately 70% ownership interest in Passport Buyer, which owns substantially all of the assets and assumed substantially all of the liabilities of Passport. At closing, we contributed approximately $70.0 million in cash and issued a 30% equity interest in the Passport Buyer to the Sponsors. At the closing of the transaction, our economic interest in Passport Buyer was approximately 70% and our voting interest was approximately 57%. As a result of Passport not being awarded a new Medicaid contract with CHFS, the Company is required to acquire the Sponsors’ 30% ownership interest in Passport Buyer for $20.0 million within twelve months following December 31, 2020, the expiration of Passport’s current Medicaid contract. Refer to Note 4 for additional information about the investment in Passport. Global On May 24, 2019, we completed the acquisition of approximately a 45% ownership interest in MHG, the sole owner of Momentum Health Acquisition, Inc. (“MHA”), which is the sole owner of GlobalHealth Holdings, LLC (“GHH”), which is the sole owner of GlobalHealth, Inc., a health maintenance organization based in the State of Oklahoma that offers, among other things, Medicare Advantage products in the State of Oklahoma. At closing, we contributed approximately $15.0 million in cash and 1,577,841 shares of our Class A common stock to MHG, together with certain of our other assets. The Company recognized $9.6 million non-cash gain on disposal of assets upon the contribution. We also recognized a short-term contingent consideration liability fair valued at $5.9 million at the time of the transaction. At the closing of the transaction, our economic interest in GlobalHealth was approximately 45% and our voting interest was approximately 29%. As of March 31, 2020, the Oklahoma Insurance Division (“OID”) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately $47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the three months ended March 31, 2020. As the Passport and MHG investments represent unconsolidated VIEs to the Company, the assets and liabilities of the investments themselves are not recorded on the Company’s balance sheets. The following table represents the carrying value of the associated assets and liabilities and the associated maximum loss exposure for the unconsolidated VIEs as of the date indicated (in thousands): June 30, 2020 December 31, 2019 Passport Buyer Momentum Health Group, LLC Passport Buyer Momentum Health Group, LLC Assets: Current assets $ 310,977 $ — $ 271,894 $ 50,729 Non current assets 701 — 577 39,259 Total assets $ 311,678 $ — $ 272,471 $ 89,988 Liabilities: Current liabilities 177,757 $ — 181,206 55,442 Non current liabilities 32 — 40 44,650 Total liabilities $ 177,789 $ — $ 181,246 $ 100,092 Investment carrying value $ 92,797 $ — $ 70,000 $ 46,456 Loan and interest receivable 42,687 — 41,387 — Guarantee (1) 25,000 — 25,000 — Maximum exposure $ 160,484 $ — $ 136,387 $ 46,456 (1) The $25.0 million guarantee to the Passport Buyer does not include a guarantee signed in January 2020 whereby the Company agrees to guarantee Passport Buyer will maintain a minimum risk-based-capital of 150% with the Kentucky Department of Insurance. The maximum exposure is limited to amounts funded to return Passport Buyer to a risk-based-capital of 150%, however as of June 30, 2020, no amounts have been funded under this guarantee. Summarized Financial Information of Equity Method Investees The following table represents the aggregated summarized financial information as of and for the dates indicated (in thousands): June 30, December 31, Current assets $ 351,805 $ 356,085 Non current assets 4,612 43,744 Current liabilities 202,259 267,300 Non current liabilities 16,894 57,599 Non controlling interests 97,315 70,535 For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Revenue $ 575,793 $ 30,003 $ 1,194,276 $ 189,975 Operating loss 40,065 254 34,080 (5,874) Net loss 39,263 340 27,643 (12,185) Net loss attributable to entity 25,327 75 17,712 (347)

Non-controlling Interests

Non-controlling Interests	6 Months Ended
	Jun. 30, 2020
Noncontrolling Interest [Abstract]
Non-controlling Interests	Non-controlling Interests Immediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company’s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company’s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders’ equity attributable to Evolent Health, Inc. During 2019, all remaining holders of Class B units executed Class B Exchanges. These Class B Exchanges resulted in the issuance of 3.1 million shares of the Company’s Class A common stock. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of the related Class B units, the Company’s economic interest in Evolent Health LLC increased to 100% immediately following the final Class B Exchange during the quarter, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. The Company paid $1.3 million on behalf of certain holders of Class B units to satisfy income tax obligations related to certain exchanges. In May 2019, the Company issued 1.6 million Class A common shares as part of the consideration for the GlobalHealth transaction. For each share of Class A common stock issued by Evolent Health, Inc., the Company received a corresponding Class A common unit from Evolent Health LLC. As a result of the Class A common units (and corresponding Class A common shares) issued as part of the GlobalHealth transaction, the Company’s economic interest in Evolent Health LLC increased from 99.1% to 99.2%, immediately following the transaction. Changes in non-controlling interests (in thousands) for the periods presented were as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Non-controlling interests balance as of beginning of period $ — $ 50,100 $ 6,689 $ 45,532 Decrease in non-controlling interests as a result of Class B Exchanges — (33,946) — (33,946) Amount attributable to NCI from business combination — — — 6,500 Net loss attributable to non-controlling interests — (285) — (2,195) Reclassification of non-controlling interests — 209 (6,689) 187 Non-controlling interests balance as of end of period $ — $ 16,078 $ — $ 16,078

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. Recurring Fair Value Measurements In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): June 30, 2020 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 4,842 $ — $ — $ 4,842 Restricted cash and restricted investments (1) 1,005 — — 1,005 Total fair value of assets measured on a recurring basis $ 5,847 $ — $ — $ 5,847 Liabilities Contingent consideration (2) $ — $ — $ 3,600 $ 3,600 Warrants (3) — — 4,900 4,900 Total fair value of liabilities measured on a recurring basis $ — $ — $ 8,500 $ 8,500 December 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 3,698 $ — $ — $ 3,698 Restricted cash and restricted investments (1) 1,004 — — 1,004 Total fair value of assets measured on a recurring basis $ 4,702 $ — $ — $ 4,702 Liabilities Contingent consideration (2) $ — $ — $ 9,883 $ 9,883 Warrants (3) — — 7,092 7,092 Total fair value of liabilities measured on a recurring basis $ — $ — $ 16,975 $ 16,975 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of June 30, 2020 and December 31, 2019, as presented in the tables above. (2) Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4. (3) Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9. The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels for the three and six months ended June 30, 2020, respectively. In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks. The strategic alliance with Passport entered into during 2016 included a provision for additional equity consideration contingent upon the Company obtaining new third-party Medicaid business in future periods. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Passport contingent consideration are the five-year risk-adjusted recurring revenue compound annual growth rate (“CAGR”) and the applicable discount rate. A significant increase in the assumed five-year risk-adjusted recurring revenue CAGR projection or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration. The changes in our contingent consideration, measured at fair value, for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Six Months Ended June 30, 2020 2019 Balance as of beginning of period $ 16,975 $ 8,800 Additions — 5,900 Settlements (3,500) (800) Realized and unrealized gains (losses), net (4,975) 200 Balance as of end of period $ 8,500 $ 14,100 The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: June 30, 2020 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 3,600 Management estimate Stock price period January - June 2020 Warrants $ 4,900 Black-Scholes Stock price volatility 61.8 % Annual risk free rate 0.3 % December 31, 2019 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Passport contingent consideration $ 3,700 Real options approach Risk-adjusted recurring revenue CAGR 93.9 % (1) Discount rate/time value 4.8% - 5.3% GlobalHealth contingent consideration $ 5,200 Monte Carlo simulation Stock price volatility 80.0 % (2) Other contingent considerations $ 983 Management estimate Adjusted EBITDA $ 19,235 Warrants $ 7,092 Black-Scholes Stock price volatility 55.0 % Annual risk free rate 1.7 % (1) The risk-adjusted recurring revenue CAGR is calculated over the five-year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of $1.0 million, resulting in a higher growth rate. (2) Equity volatility based on Evolent’s daily stock price returns for a look-back period corresponding to the time until the second test date. The large one-day stock price drop on November 27, 2019, was excluded from the volatility calculation. Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 9 for information regarding the fair value of the 2025 Notes and 2021 Notes.

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Parties	Related Parties The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements. As discussed in Note 15, the Company has economic interests in several entities that are accounted for under the equity method of accounting, including Passport. The Company has allocated its proportional share of the investees’ earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. Revenues related to the services agreements were approximat ely $71.4 million and $131.3 million for the three and six months ended June 30, 2020, respectively, and $11.0 million and $18.1 million for the three and six months ended June 30, 2019, respectively. The Company also works closely with UPMC, one of its founding investors. The Company’s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest. The following table presents assets and liabilities attributable to our related parties (in thousands): June 30, December 31, Assets Accounts receivable $ 7,597 $ 8,781 Prepaid expenses - current 801 1,592 Customer advance for regulatory capital requirements, net 39,955 40,000 Prepaid expenses and other noncurrent assets 4,813 2,709 Liabilities Accounts payable $ 7,132 $ 6,429 Accrued liabilities 4,267 2,583 Reserve for claims and performance-based arrangements — 4,264 The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Revenue Transformation services $ — $ 41 $ 1,700 $ 1,200 Platform and operations services 73,885 16,874 141,833 29,818 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) (2,171) 6,657 1,076 14,487 Selling, general and administrative expenses 27 386 97 542

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	Segment ReportingWe define our reportable segments based on the way the CODM, currently the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows: • Services, which consists of two clinical solutions: (i) total cost of care management, and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services; and • True Health, which consists of a commercial health plan we operate in New Mexico that focuses on individual and family as well as small and large group businesses as well as the Federal Employee Health Benefits Program. In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results. The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. Adjusted EBITDA is defined as EBITDA (net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses), adjusted to exclude equity method investment impairment, gain (loss) from equity method investees, gain (loss) on disposal of assets, goodwill impairment, changes in fair value of contingent consideration and indemnification asset, other income (expense), net, net loss attributable to non-controlling interests, purchase accounting adjustments, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, acquisition-related costs, and other infrequently occurring adjustments. Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. The following tables present our segment information (in thousands): Services True Health Intersegment Eliminations Consolidated Revenue For the Three Months Ended June 30, 2020 Services: Transformation services $ 755 $ — $ — $ 755 Platform and operations services 216,544 — (4,169) 212,375 Services revenue 217,299 — (4,169) 213,130 True Health: Premiums — 25,541 (39) 25,502 Total revenue $ 217,299 $ 25,541 $ (4,208) $ 238,632 For the Three Months Ended June 30, 2019 Services: Transformation services $ 1,944 $ — $ — $ 1,944 Platform and operations services 147,599 — (3,077) 144,522 Services revenue 149,543 — (3,077) 146,466 True Health: Premiums — 45,764 (271) 45,493 Total revenue $ 149,543 $ 45,764 $ (3,348) $ 191,959 Services True Health Segments Total For the Three Months Ended June 30, 2020 Adjusted EBITDA $ 10,519 $ (1,480) $ 9,039 For the Three Months Ended June 30, 2019 Adjusted EBITDA $ (8,797) $ 1,123 $ (7,674) Services True Health Intersegment Consolidated Revenue For the Six Months Ended June 30, 2020 Services: Transformation services $ 5,993 $ — $ — $ 5,993 Platform and operations services 432,739 — (10,464) 422,275 Services revenue 438,732 — (10,464) 428,268 True Health: Premiums — 57,928 (279) 57,649 Total revenue $ 438,732 $ 57,928 $ (10,743) $ 485,917 For the Six Months Ended June 30, 2019 Services: Transformation services $ 5,297 $ — $ — $ 5,297 Platform and operations services 297,949 — (6,135) 291,814 Services revenue 303,246 — (6,135) 297,111 True Health: Premiums — 93,140 (536) 92,604 Total revenue $ 303,246 $ 93,140 $ (6,671) $ 389,715 Services True Health Segments Total For the Six Months Ended June 30, 2020 Adjusted EBITDA $ 14,395 $ (1,729) $ 12,666 For the Six Months Ended June 30, 2019 Adjusted EBITDA $ (24,296) $ 1,844 $ (22,452) The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Net loss attributable to common shareholders of Evolent Health, Inc. $ (203,521) $ (31,615) $ (282,273) $ (78,354) Less: Interest income 842 842 1,761 1,902 Interest expense (6,293) (3,620) (12,578) (7,182) (Provision) benefit for income taxes 3,904 (1,398) 3,634 (902) Depreciation and amortization expenses (15,778) (15,292) (31,916) (29,558) Equity method investment impairment — — (47,133) — Gain (loss) from equity method investees 25,143 (1,904) 24,731 (2,328) Gain (loss) on disposal of assets — 9,600 (6,447) 9,600 Goodwill impairment (215,100) — (215,100) — Change in fair value of contingent consideration and indemnification asset (756) (100) 3,062 (200) Other income (expense), net 352 (587) 281 (160) Net loss attributable to non-controlling interests — 285 — 2,195 Purchase accounting adjustments — (165) — (761) Stock-based compensation expense (3,703) (4,750) (7,211) (9,287) Severance costs (30) (3,881) (6,133) (14,483) Amortization of contract cost assets (767) (776) (1,207) (1,552) Acquisition costs (374) (2,195) (683) (3,186) Adjusted EBITDA $ 9,039 $ (7,674) $ 12,666 $ (22,452) Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.

Reserves for Claims and Perform

Reserves for Claims and Performance-Based Arrangements	6 Months Ended
	Jun. 30, 2020
Insurance [Abstract]
Reserves for Claims and Performance-Based Arrangements	Reserve for Claims and Performance-Based Arrangements The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its specialty care management services. The Company also maintains reserves for claims incurred but not paid related to its capitation arrangement and for its health plan, True Health, in New Mexico. Reserves for claims and performance-based arrangements for our Services and True Health segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under the reinsurance agreement, as discussed further in Note 10. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability, for reserves related to its specialty care management services and True Health, is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company’s policy for reserves related to its specialty care management services and True Health is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2020, was as follows (in thousands): For the Six Months Ended June 30, 2020 2019 Services (1) True Health (3) Total Services (1) True Health (3) Total Beginning balance $ 54,510 $ 6,640 $ 61,150 $ 17,715 $ 9,880 $ 27,595 Incurred costs related to current year 204,112 41,584 245,696 $ 88,261 $ 73,359 $ 161,620 Incurred costs related to prior year (521) 1,351 830 244 483 727 Paid costs related to current year 167,451 33,538 200,989 73,781 26,473 100,254 Paid costs related to prior year 10,029 6,975 17,004 7,837 8,003 15,840 Change during the year 26,111 2,422 28,533 6,887 39,366 46,253 Other adjustments (2) 4,726 — 4,726 (187) (40,609) (40,796) Ending balance $ 85,347 $ 9,062 $ 94,409 $ 24,415 $ 8,637 $ 33,052 (1) Costs incurred to provide specialty care management services are recorded within cost of revenue in our statement of operations. (2) Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to the True Health segment represent premiums received less administrative expenses related to the reinsurance agreement for amounts in 2019. Refer to Note 10 for additional information about the reinsurance agreement. (3) There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. The number of claims processed for the six months ended June 30, 2020 and 2019 were 170,295 and 206,137, respectively.

Investments

Investments	6 Months Ended
	Jun. 30, 2020
Investments [Abstract]
Investments	Investments Our investments are classified as held-to-maturity as we have both the intent and ability to hold the investments until their individual maturities. The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of June 30, 2020 and December 31, 2019 (in thousands) were as follows: June 30, 2020 December 31, 2019 Amortized Gross Unrealized Fair Value Amortized Gross Unrealized Fair Value Gains Losses Gains Losses U.S. Treasury bills $ 8,909 $ 492 $ — $ 9,401 $ 10,784 $ 270 $ — $ 11,054 Corporate bonds 1,706 122 — 1,828 1,705 70 — 1,775 Collateralized mortgage obligations 5,695 219 — 5,914 5,472 56 (5) 5,523 Yankees 597 51 — 648 597 30 — 627 Total investments $ 16,907 $ 884 $ — $ 17,791 $ 18,558 $ 426 $ (5) $ 18,979 The amortized cost and fair value of our investments by contractual maturities as of June 30, 2020 and December 31, 2019 (in thousands) were as follows: June 30, 2020 December 31, 2019 Amortized Cost Fair Value Amortized Cost Fair Value Due in one year or less $ 836 $ 845 $ 1,807 $ 1,810 Due after one year through five years 16,071 16,946 16,121 16,542 Due after five years through ten years — — 630 627 Total investments $ 16,907 $ 17,791 $ 18,558 $ 18,979 When a held-to-maturity investment is in an unrealized loss position, we assess whether or not we expect to recover the entire cost basis of the security, based on our best estimate of the present value of cash flows expected to be collected from the debt security. Factors considered in our analysis include the reasons for the unrealized loss position, the severity and duration of the unrealized loss position, credit worthiness and forecasted performance of the investee. In cases where the estimated present value of future cash flows is less than our cost basis, we recognize an other than temporary impairment and write the investment down to its fair value. The new cost basis would not be changed for subsequent recoveries in fair value. There were no securities held in an unrealized loss position for more than twelve months as of June 30, 2020 or December 31, 2019. The Company held the following securities (in thousands) in an unrealized loss position for less than twelve months as of December 31, 2019, and expects to recover the entire cost basis of the security: June 30, 2020 December 31, 2019 Number of Securities Fair Value Unrealized Losses Number of Securities Fair Value Unrealized Losses Collateralized mortgage obligations 1 $ 8 $ — 4 $ 2,075 $ 5

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following represents supplemental cash flow information (in thousands): For the Six Months Ended June 30, 2020 2019 Supplemental Disclosure of Non-cash Investing and Financing Activities Increase to goodwill from measurement period adjustments/business combinations $ 2,200 $ 596 Class A common stock issued for payment of earn-outs 4,185 800 Accrued property and equipment purchases (26) 166 Consideration for asset acquisitions or business combinations — 16,000 Effects of Leases Operating cash flows from operating leases 6,853 6,542 Leased assets obtained in exchange for operating lease liabilities (1,354) 30,181 Effects of Class B Exchanges Decrease in non-controlling interests as a result of Class B Exchanges — 33,946

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 16, 2020, Evolent Health LLC, a Delaware limited liability company (“EVH LLC”) and wholly owned subsidiary of Evolent Health, Inc. (“EVH, Inc.”), and Passport Health Plan, Inc. (formerly known as Justify Holdings, Inc.), a Kentucky corporation (“Passport”), which is owned 70% by EH Holding Company, Inc., a wholly owned subsidiary of EVH LLC (“EH Holding Company”), entered into an Asset Purchase Agreement (the “Molina APA”) with Molina Healthcare, Inc., a Delaware corporation (“Molina”), pursuant to which Passport will sell certain assets to Molina (or its permitted affiliate assignee) as set forth in more detail below. Background On May 28, 2019, University Health Care, Inc. (“UHC”), Passport Health Solutions, LLC, a subsidiary of UHC (“PHS”), Passport and EVH, Inc., entered into an Asset Purchase Agreement (the “UHC APA”), pursuant to which Passport would acquire substantially all of the assets and liabilities of UHC and PHS, including the Kentucky Medicaid business of UHC (the “Medicaid Business”), the Kentucky dual eligible special needs business of UHC (the “D-SNP Business”) and certain owned real property and related assets of PHS (the “Real Property”). On December 30, 2019, Passport acquired the Medicaid Business for cash and the issuance of a 30% ownership interest in Passport to the provider sponsors of UHC (the “Sponsors”). On that date, the parties to the UHC APA entered into an amendment to the UHC APA (the “Amendment”) that provided for (i) the transfer of the D-SNP Business at such time as Passport becomes certified as a Medicare Advantage Organization and (ii) the transfer of the Real Property at such time as it becomes free and clear of any encumbrances. Further, pursuant to the Amendment, Passport would administer and assume the financial risk of the D-SNP Business until it is transferred to Passport. In connection with the closing of the transaction contemplated by the UHC APA, EVH, Inc. and EH Holding Company agreed to purchase the Sponsor’s stock in Passport for $20.0 million on or before December 31, 2021 in the event Passport was not awarded a Medicaid contract pursuant to the request for proposal (the “RFP”) issued by the Kentucky Cabinet for Family Services (“CHFS”) for Medicaid contracts for plan years 2021 through 2024. On May 29, 2020, Passport received notice that it was not awarded a Medicaid contract pursuant to the RFP. Passport will be withdrawing its previously filed protest. Molina APA Asset Transfer Pursuant to the Molina APA and subject to the terms and conditions set forth therein, Passport has agreed to sell to Molina (or its permitted affiliate assignee) certain assets, including the following: (i) certain intellectual property rights of Passport, including trade names (the “IP Assets”); (ii) Passport’s rights under its Medicaid contract with CHFS (the “Medicaid Contract”); (iii) Passport’s rights under UHC’s contracts (collectively, the “D-SNP Contract”) with the Commonwealth of Kentucky, Department of Medicaid Services (“DMS”) and Centers for Medicare and Medicaid Services (“CMS”) with respect to the D-SNP Business; (iv) Passport’s rights under certain provider and vendor agreements (the “Provider and Vendor Agreements”); and (v) Passport’s rights under certain real property leases (the “Real Property Leases”). Passport is retaining, among other assets, the following: (i) all cash, cash equivalents and risk based capital; and (ii) all accounts receivable and rights to payment under the Medicaid Contract for services performed prior to the transfer of the Medicaid Contract. In addition, Molina will assume Passport’s obligations under the Medicaid Contract, Provider and Vendor Agreements and Real Property Leases arising following the transfer of such contracts. The closing of the transactions contemplated by the Molina APA (the “Closing”) will take place on the earlier of (i) September 1, 2020 and (ii) within three business days following receipt of the necessary approvals of certain governmental authorities, including the approval of CHFS and Kentucky Department of Insurance, if required (the “Required Medicaid Approvals”), for the transfer of the Medicaid Contract from Passport to Molina (the “Medicaid Novation”). At the Closing, Passport will transfer to Molina the IP Assets. In addition, if the Required Medicaid Approvals for the Medicaid Novation are obtained prior to the Closing, at the Closing, Passport will transfer to Molina the Medicaid Contract. If the Required Medicaid Approvals for the Medicaid Novation are obtained after the Closing but prior to December 31, 2020, promptly following receipt thereof, Passport will transfer to Molina the Medicaid Contract (the date on which such transfer occurs referred to herein as the “Medicaid Closing”). Subject to the Closing and the receipt of required third party consents, the Provider and Vendor Agreements and the Real Property Leases will transfer to Molina on January 1, 2021. If the Medicaid Novation occurs, EVH LLC and Passport will administer the Medicaid Business on behalf of Molina until January 1, 2021. Pursuant to the Molina APA, the D-SNP Contract will be transferred to Molina at such time as Molina is certified as a Medicare Advantage Organization and obtains approvals of certain governmental authorities, including CMS and DMS (the “Required D-SNP Approvals”), for the novation of the D-SNP Contract. At the Closing, Molina will assume the financial risk of the D-SNP Business until such time as the D-SNP Business is transferred to Molina or the D-SNP Contract is terminated. Passport and EVH, Inc. will continue to administer the D-SNP Business until January 1, 2021, at which time Molina will be responsible for the administration of the D-SNP Business until the D-SNP Contract is transferred to Molina (the “D-SNP Closing”) or the D-SNP Contract is terminated. The Closing is conditioned on customary closing conditions related to the accuracy of the representations and warranties of the parties, compliance with covenants, the absence of legal proceedings and the continued effectiveness of the awards issued in connection with the RFP. The Medicaid Closing is conditioned on the receipt of the Required Medicaid Approvals. The D-SNP Closing is conditioned on the receipt of the Required D-SNP Approvals as well as the effectiveness of the D-SNP Contract. Consideration At the Closing, Molina will pay Passport $20.0 million in cash that will be placed into escrow until January 1, 2021 (the “Closing Payment”). The Closing Payment is payable regardless of whether the Medicaid Closing or D-SNP Closing has occurred and will be released on January 1, 2021. In the event the Medicaid Closing and/or D-SNP Closing occurs after the Closing, then no further consideration will be payable to Passport as a result of such Medicaid Closing and/or D-SNP Closing. In addition to the Closing Payment, Passport will be eligible to receive an additional cash payment of up to approximately $40.0 million from Molina based on the number of enrollees above a certain threshold in the D-SNP Business and Molina’s Medicaid plan following the open enrollment period for plan year 2021 (the “Membership Payment”). The Membership Payment is not conditioned on the Medicaid Closing and/or D-SNP Closing. In the event the Medicaid Closing does not occur by January 1, 2021, Passport is required to repay Molina $7.5 million of the Closing Payment. Employees Pursuant to the terms of the Molina APA, on January 1, 2021, Molina will hire substantially all of Passport’s employees and those EVH LLC employees primarily performing services for the Medicaid Business and D-SNP Business. Indemnification The Molina APA provides for customary indemnification by the parties, including indemnification for excluded liabilities, assumed liabilities and breaches of representations, warranties and covenants. Guarantees EVH LLC has guaranteed the obligations of Passport and Molina has guaranteed the obligations of its permitted affiliate assignee under the Molina APA. Concurrently with the execution of the Molina APA, Passport and an affiliate of Molina also entered into a real property purchase agreement with respect to the Real Property (the “Real Property Purchase Agreement”). Under the terms of the Real Property Purchase Agreement, an affiliate of Molina will purchase the Real Property from Passport for $8.0 million, subject to adjustment for certain matters. The closing of the transactions contemplated by the Real Property Purchase Agreement is conditioned on customary real estate closing conditions, including receipt of adequate title, satisfaction of certain matters identified in diligence, survey and environmental reports and Passport’s acquisition of the Real Property from UHC pursuant to the UHC APA.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2019, has been derived from audited financial statements as of that date. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2019 Form 10-K.
Accounting Estimates and Assumptions	Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets (including equity method investments), stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, valuation of intangible assets (including goodwill), purchase price allocation in taxable stock transactions and useful lives of intangible assets.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Operating Segments	Operating Segments Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of two clinical solutions: (i) total cost of care services and (ii) specialty care management services, and one administrative solution: comprehensive health plan administration services. Our True Health segment consists of a commercial health plan we operate in New Mexico that historically focused on small and large businesses. In 2020, True Health diversified its services to offer coverage for individuals and families as well as the Federal Employee Health Benefits Program. See Note 19 for a discussion of our operating results by segment.
Notes Receivable	Notes Receivable Notes receivable are carried at the face amount of each note plus accrued interest receivable, less received payments. The Company does not typically carry notes receivable in the course of its regular business, but contributed $40.0 million in the form of an advance for regulatory capital requirements (the “Passport Note”) under an agreement that Passport entered into during the second quarter of 2019. The Passport Note carries a fixed interest rate of 6.5% per annum and is required to be repaid, plus accrued interest, in a single payment on July 1, 2025, the maturity date, or earlier, subject to regulatory approval. The Passport Note is required to be repaid out of the surplus in excess of Passport’s obligations to its policyholders, claimant and beneficiary claims and all other creditors. As of June 30, 2020, the outstanding principal balance of the Passport Note was $40.0 million, excluding approximately $2.7 million of accrued interest.
Business Combinations	Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.
Equity Method Investments and Impairment of Equity Method Investments	Equity Method Investments For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in and advances to equity method investees on the consolidated balance sheets with income or loss included in loss from equity method investees on the consolidated statements of operations and comprehensive income (loss). Impairment of Equity Method Investments The Company considers certain factors to determine if there is a decrease in its investment value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 15 for additional discussion regarding impairments on equity method investments.
Goodwill	Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level, which is consistent with the way management evaluates our business. The Company has four reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during the six months ended June 30, 2020 and the year ended December 31, 2019.
Intangible Assets, Net	Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 4-5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.
Reserves for Claims and Performance-based Arrangements	Reserves for Claims and Performance-based Arrangements Reserves for performance-based arrangements and claims for our Services and True Health segments reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under a reinsurance agreement for 2019 as discussed further in Note 10. The reinsurance agreement was terminated in December 2019. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 20 for additional discussion regarding our reserves for claims and performance-based arrangements.
Leases	Leases As discussed in Note 3, we adopted Accounting Standards Update (“ASU”) 2016-02 effective January 1, 2019. The following reflects our updated policy for leases. The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. Refer to Note 11 for additional lease disclosures.
Revenue Recognition	Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition for our Services segment from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derived revenue in 2019 from reinsurance premiums assumed from NMHC under the terms of the reinsurance agreement (as defined in Note 10). The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as deferred revenue on our consolidated balance sheets. See Note 5 for further discussion of our policies related to revenue recognition.
Foreign Currency	Foreign Currency The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020 and 2019.
Adoption of New Accounting Standards	Adoption of New Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases , in order to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases, including a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02 In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Services Contract . The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted the requirements of ASU 2018-15 effective January 1, 2019. There was no material impact to our consolidated balance sheets or results of operations as of or for the year ended December 31, 2019. In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update). ASU 2019-07 clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. The disclosure and presentation amendments included in ASU 2019-07, which were effective upon issuance of the standard and were to be applied prospectively, did not have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing “incurred loss” framework with an expected credit loss recognition model. The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts. The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of ASU 2016-13 In August 2018, the FASB issued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement . ASU 2018-13 amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosures. This ASU is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. We adopted the requirements of this standard effective January 1, 2020 and determined it did not have a material impact on our consolidated financial statements and related disclosures.
Fair Value Measurement	GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 9 for information regarding the fair value of the 2025 Notes and 2021 Notes.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of restricted cash and cash equivalents	Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: June 30, 2020 December 31, 2019 Collateral for letters of credit for facility leases (1) $ 3,610 $ 3,610 Collateral with financial institutions (2) 5,745 5,742 Claims processing services (3) 44,886 18,171 Other 1,412 817 Total restricted cash and restricted investments $ 55,653 $ 28,340 Current restricted investments $ 100 $ 704 Current restricted cash 46,794 19,376 Total current restricted cash and restricted investments $ 46,894 $ 20,080 Non-current restricted investments $ 615 $ 113 Non-current restricted cash 8,144 8,147 Total non-current restricted cash and restricted investments $ 8,759 $ 8,260 (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements. As of both June 30, 2020 and December 31, 2019, approximately $1.0 million of the collateral amount was held in a trust account and invested in money market funds related to risk-sharing arrangements. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. As of both June 30, 2020 and December 31, 2019, approximately $4.7 million, of the collateral amounts were held in a FDIC participating bank account. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows. June 30, 2020 2019 Cash and cash equivalents $ 98,272 $ 92,821 Restricted cash and restricted investments 55,653 45,158 Restricted investments included in restricted cash and restricted investments (715) (812) Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 153,210 $ 137,167
Schedule of intangible assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 4-5 years Details of our intangible assets (in thousands) are presented below: June 30, 2020 December 31, 2019 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 13.7 $ 23,300 $ 5,581 $ 17,719 14.2 $ 23,300 $ 4,891 $ 18,409 Customer relationships 16.6 281,219 50,988 230,231 16.8 291,519 44,750 246,769 Technology 2.3 82,922 58,204 24,718 2.0 82,922 49,760 33,162 Below market lease, net 2.8 1,118 548 570 2.2 2,048 1,334 714 Provider network contracts 3.3 14,475 4,800 9,675 3.7 12,725 3,320 9,405 Total intangible assets, net $ 403,034 $ 120,121 $ 282,913 $ 412,514 $ 104,055 $ 308,459

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table represents Evolent’s Services segment revenue disaggregated by type of services (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance . For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Services Revenue Transformation services $ 755 $ 1,944 $ 5,993 $ 5,297 Platform and operations services Clinical solutions 161,774 94,573 321,582 191,204 Administrative solutions 50,562 49,058 100,616 99,683
Contract with customer, asset and liability	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): June 30, 2020 December 31, 2019 Short-term receivables (1) $ 93,066 $ 71,707 Long-term receivables (1) 740 709 Short-term contract assets 2,346 1,751 Long-term contract assets 47 999 Short-term deferred revenue 13,247 19,828 Long-term deferred revenue 1,338 1,330 (1) Excludes pharmacy claims receivable and premiums receivable Changes in contract assets and deferred revenue for the six months ended June 30, 2020, are as follows (in thousands): For the Six Months Ended June 30, 2020 Contract assets Balance as of beginning-of-period $ 2,750 Reclassification to receivables, as the right to consideration becomes unconditional (1,477) Contract assets recognized, net of reclassification to receivables 1,120 Balance as of end-of-period $ 2,393 Deferred revenue Balance as of beginning-of-period $ 21,158 Reclassification to revenue, as a result of performance obligations satisfied (15,538) Cash received in advance of satisfaction of performance obligations 8,965 Balance as of end-of-period $ 14,585

Credit Losses (Tables)

Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2020
Credit Loss [Abstract]
Accounts receivable, allowance for credit loss	The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2020 (in thousands): For the Six Months Ended June 30, 2020 Balance as of December 31, 2019 $ (41) Cumulative transition adjustment (2,815) Provision for credit losses (260) Charge-offs 1,575 Balance as of June 30, 2020 $ (1,541)
Held-to-maturity securities, amortized cost and interest income	The amortized cost of our investments as of June 30, 2020 and December 31, 2019 (in thousands) and interest income for the three and six months ended June 30, 2020 were as follows: Amortized Cost Interest Income for the Three Months Ended June 30, Interest Income for the Six Months Ended June 30, June 30, 2020 December 31, 2019 2020 2019 2020 2019 U.S. Treasury bills $ 8,909 $ 10,784 $ 57 $ 61 $ 122 $ 119 Corporate bonds 1,706 1,705 14 11 29 20 Collateralized mortgage obligations 5,695 5,472 51 17 104 29 Yankees 597 597 6 6 11 11 Total investments $ 16,907 $ 18,558 $ 128 $ 95 $ 266 $ 179

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Summary of property and equipment	The following summarizes our property and equipment (in thousands): June 30, 2020 December 31, 2019 Computer hardware $ 12,061 $ 11,604 Furniture and equipment 3,588 3,649 Internal-use software development costs 126,203 112,501 Leasehold improvements 15,537 12,415 Total property and equipment 157,389 140,169 Accumulated depreciation and amortization expenses (68,834) (55,014) Total property and equipment, net $ 88,555 $ 85,155

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): For the Six Months Ended June 30, 2020 Services True Health Consolidated Balance as of December 31, 2019 (1) $ 566,359 $ 5,705 $ 572,064 Goodwill disposal (2) (2,200) — (2,200) Impairment (215,100) — (215,100) Foreign currency translation (69) — (69) Balance as of June 30, 2020 $ 348,990 $ 5,705 $ 354,695 For the Year Ended December 31, 2019 Services True Health Consolidated Balance as of December 31, 2018 (1) $ 762,419 $ 5,705 $ 768,124 Goodwill acquired 3,416 — 3,416 Measurement period adjustments 351 — 351 Impairment (199,800) — (199,800) Foreign currency translation (27) — (27) Balance as of December 31, 2019 $ 566,359 $ 5,705 $ 572,064 (1) Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of June 30, 2020 and December 31, 2019, respectively. (2) Goodwill written down on disposal of a consolidated subsidiary.
Schedule of intangible assets details	The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 4-5 years Details of our intangible assets (in thousands) are presented below: June 30, 2020 December 31, 2019 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 13.7 $ 23,300 $ 5,581 $ 17,719 14.2 $ 23,300 $ 4,891 $ 18,409 Customer relationships 16.6 281,219 50,988 230,231 16.8 291,519 44,750 246,769 Technology 2.3 82,922 58,204 24,718 2.0 82,922 49,760 33,162 Below market lease, net 2.8 1,118 548 570 2.2 2,048 1,334 714 Provider network contracts 3.3 14,475 4,800 9,675 3.7 12,725 3,320 9,405 Total intangible assets, net $ 403,034 $ 120,121 $ 282,913 $ 412,514 $ 104,055 $ 308,459
Schedule of future estimated amortization of intangible assets	Future estimated amortization of intangible assets (in thousands) as of June 30, 2020, is as follows: 2020 $ 14,842 2021 28,701 2022 24,819 2023 22,055 2024 16,171 Thereafter 176,325 Total future amortization of intangible assets $ 282,913

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of convertible debt	The following table summarizes the carrying value of the long-term convertible debt (in thousands): June 30, 2020 December 31, 2019 2025 Notes Carrying value $ 111,665 $ 107,169 Unamortized debt discount and issuance costs allocated to debt 60,835 65,331 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 5.3 5.8 2021 Notes Carrying value $ 123,697 $ 123,237 Unamortized issuance costs 1,303 1,763 Principal amount $ 125,000 $ 125,000 Remaining amortization period (years) 1.4 1.9

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Summary of premiums and claims assumed	The following summarizes premiums and claims assumed under the Reinsurance Agreement (in thousands): For the Six Months Ended June 30, 2020 2019 Reinsurance premiums assumed $ — $ 48,828 Claims assumed — 41,424 Claims-related administrative expenses — 8,219 Decrease in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement — 815 Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period — 1,243 Reinsurance payments — 1,235 Receivables for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period $ — $ 823
Summary of major customers	The following table summarizes the partner included in our Services segment who represented at least 10.0% of our consolidated trade accounts receivable for the periods presented: June 30, 2020 December 31, 2019 Cook County Health and Hospitals System 56.7 % 48.4 % The following table summarizes those customers of our Services segment who represented at least 10.0% of our consolidated revenue for the periods presented: For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Passport 25.2 % 13.2 % 23.6 % 13.1 % New Mexico Health Connections * 13.2 % * 13.6 % Cook County Health and Hospitals Systems 19.9 % * 19.3 % * * Represents less than 10.0% of the respective balance

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of maturity of lease liabilities	The following table summarizes our primary office leases as of June 30, 2020 (in thousands): Location Lease Termination Term (in years) Future Minimum Lease Commitments Letter of Credit Amount Required Arlington, VA 11.6 $ 40,203 $ 1,579 Riverside, IL 10.8 46,053 232 Louisville, KY (1) 0.5 — — Pune, India 3.3 2,667 — Brea, CA 1.9 2,093 — (1) Lease payments of $4.1 million for Louisville, KY have been prepaid as of June 30, 2020. Maturity of lease liabilities (in thousands) as of June 30, 2020, is as follows: Operating lease expense (1) 2020 6,039 2021 11,726 2022 9,801 2023 9,376 2024 8,833 Thereafter 56,093 Total lease payments 101,868 Less: Interest 27,419 Present value of lease liabilities $ 74,449 (1) We have additional operating lease agreements for office space that have not yet commenced as of June 30, 2020. The minimum lease payments for those leases are $0.2 million and the leases will commence during 2020.
Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms	The following table summarizes the components of our lease cost (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost $ 3,586 $ 3,838 $ 6,642 $ 7,119 Amortization of right-of-use assets 150 — 299 — Interest expense 1 — 3 — Variable lease cost 1,465 1,121 2,517 2,576 Total lease cost $ 5,202 $ 4,959 $ 9,461 $ 9,695 Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows: June 30, 2020 Weighted average discount rate 6.43 % Weighted average remaining lease term 9.6

Earnings (Loss) Per Common Sh_2

Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Computation of basic and diluted earnings per share	The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Net loss $ (203,521) $ (31,900) $ (282,273) $ (80,549) Less: Net loss attributable to non-controlling interests — (285) — (2,195) Net loss available for common shareholders - basic and diluted (1) $ (203,521) $ (31,615) $ (282,273) $ (78,354) Weighted-average common shares outstanding - basic and diluted (1) 85,349 82,289 84,977 80,820 Loss per common share Basic and diluted $ (2.38) $ (0.38) $ (3.32) $ (0.97)
Schedule of antidilutive securities excluded from computation of earnings per share	Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below: For the Three Months Ended June 30, 2020 For the Six Months Ended June 30, 2020 2019 2020 2019 Exchangeable Class B common stock — 1,080 — 2,129 Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs") 554 985 376 1,014 Stock options 711 1,495 841 1,729 Convertible senior notes 10,361 10,361 10,361 10,361 Total 11,626 13,921 11,578 15,233

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-based compensation expense	Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Award Type Stock options $ 638 $ 903 $ 1,388 $ 2,263 Performance-based stock options — 112 75 222 RSUs 2,006 2,630 3,862 5,060 Performance-based RSUs — 388 — 772 LSUs 1,059 717 1,886 970 Total compensation expense by award type $ 3,703 $ 4,750 $ 7,211 $ 9,287 Line Item Cost of revenue $ 526 $ 891 $ 918 $ 1,682 Selling, general and administrative expenses 3,177 3,859 6,293 7,605 Total compensation expense by financial statement line item $ 3,703 $ 4,750 $ 7,211 $ 9,287
Schedule of share-based awards granted	Stock-based awards were granted as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Stock options — 18 — 399 RSUs 164 17 1,140 518 LSUs 140 — 520 720

Investments In and Advances t_2

Investments In and Advances to Equity Method Investees Investments In and Advances to Equity Method Investees (Tables)	6 Months Ended
	Jun. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Schedule of carrying value of the associated assets and liabilities and the associated maximum loss exposure for the unconsolidated VIEs	The following table represents the carrying value of the associated assets and liabilities and the associated maximum loss exposure for the unconsolidated VIEs as of the date indicated (in thousands): June 30, 2020 December 31, 2019 Passport Buyer Momentum Health Group, LLC Passport Buyer Momentum Health Group, LLC Assets: Current assets $ 310,977 $ — $ 271,894 $ 50,729 Non current assets 701 — 577 39,259 Total assets $ 311,678 $ — $ 272,471 $ 89,988 Liabilities: Current liabilities 177,757 $ — 181,206 55,442 Non current liabilities 32 — 40 44,650 Total liabilities $ 177,789 $ — $ 181,246 $ 100,092 Investment carrying value $ 92,797 $ — $ 70,000 $ 46,456 Loan and interest receivable 42,687 — 41,387 — Guarantee (1) 25,000 — 25,000 — Maximum exposure $ 160,484 $ — $ 136,387 $ 46,456 (1) The $25.0 million guarantee to the Passport Buyer does not include a guarantee signed in January 2020 whereby the Company agrees to guarantee Passport Buyer will maintain a minimum risk-based-capital of 150% with the Kentucky Department of Insurance. The maximum exposure is limited to amounts funded to return Passport Buyer to a risk-based-capital of 150%, however as of June 30, 2020, no amounts have been funded under this guarantee.
Schedule of summarized equity method investees financial information	The following table represents the aggregated summarized financial information as of and for the dates indicated (in thousands): June 30, December 31, Current assets $ 351,805 $ 356,085 Non current assets 4,612 43,744 Current liabilities 202,259 267,300 Non current liabilities 16,894 57,599 Non controlling interests 97,315 70,535 For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Revenue $ 575,793 $ 30,003 $ 1,194,276 $ 189,975 Operating loss 40,065 254 34,080 (5,874) Net loss 39,263 340 27,643 (12,185) Net loss attributable to entity 25,327 75 17,712 (347)

Non-controlling Interests (Tabl

Non-controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2020
Noncontrolling Interest [Abstract]
Schedule of changes in non-controlling interests	Changes in non-controlling interests (in thousands) for the periods presented were as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Non-controlling interests balance as of beginning of period $ — $ 50,100 $ 6,689 $ 45,532 Decrease in non-controlling interests as a result of Class B Exchanges — (33,946) — (33,946) Amount attributable to NCI from business combination — — — 6,500 Net loss attributable to non-controlling interests — (285) — (2,195) Reclassification of non-controlling interests — 209 (6,689) 187 Non-controlling interests balance as of end of period $ — $ 16,078 $ — $ 16,078

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Summary of assets at fair value on recurring basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): June 30, 2020 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 4,842 $ — $ — $ 4,842 Restricted cash and restricted investments (1) 1,005 — — 1,005 Total fair value of assets measured on a recurring basis $ 5,847 $ — $ — $ 5,847 Liabilities Contingent consideration (2) $ — $ — $ 3,600 $ 3,600 Warrants (3) — — 4,900 4,900 Total fair value of liabilities measured on a recurring basis $ — $ — $ 8,500 $ 8,500 December 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 3,698 $ — $ — $ 3,698 Restricted cash and restricted investments (1) 1,004 — — 1,004 Total fair value of assets measured on a recurring basis $ 4,702 $ — $ — $ 4,702 Liabilities Contingent consideration (2) $ — $ — $ 9,883 $ 9,883 Warrants (3) — — 7,092 7,092 Total fair value of liabilities measured on a recurring basis $ — $ — $ 16,975 $ 16,975 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of June 30, 2020 and December 31, 2019, as presented in the tables above. (2) Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4. (3) Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9.
Summary of liabilities at fair value on recurring basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): June 30, 2020 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 4,842 $ — $ — $ 4,842 Restricted cash and restricted investments (1) 1,005 — — 1,005 Total fair value of assets measured on a recurring basis $ 5,847 $ — $ — $ 5,847 Liabilities Contingent consideration (2) $ — $ — $ 3,600 $ 3,600 Warrants (3) — — 4,900 4,900 Total fair value of liabilities measured on a recurring basis $ — $ — $ 8,500 $ 8,500 December 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 3,698 $ — $ — $ 3,698 Restricted cash and restricted investments (1) 1,004 — — 1,004 Total fair value of assets measured on a recurring basis $ 4,702 $ — $ — $ 4,702 Liabilities Contingent consideration (2) $ — $ — $ 9,883 $ 9,883 Warrants (3) — — 7,092 7,092 Total fair value of liabilities measured on a recurring basis $ — $ — $ 16,975 $ 16,975 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of June 30, 2020 and December 31, 2019, as presented in the tables above. (2) Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4. (3) Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9.
Changes in contingent consideration measured at fair value	The changes in our contingent consideration, measured at fair value, for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Six Months Ended June 30, 2020 2019 Balance as of beginning of period $ 16,975 $ 8,800 Additions — 5,900 Settlements (3,500) (800) Realized and unrealized gains (losses), net (4,975) 200 Balance as of end of period $ 8,500 $ 14,100
Valuation techniques and significant unobservable inputs of Level 3 fair value measurements	The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: June 30, 2020 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 3,600 Management estimate Stock price period January - June 2020 Warrants $ 4,900 Black-Scholes Stock price volatility 61.8 % Annual risk free rate 0.3 % December 31, 2019 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Passport contingent consideration $ 3,700 Real options approach Risk-adjusted recurring revenue CAGR 93.9 % (1) Discount rate/time value 4.8% - 5.3% GlobalHealth contingent consideration $ 5,200 Monte Carlo simulation Stock price volatility 80.0 % (2) Other contingent considerations $ 983 Management estimate Adjusted EBITDA $ 19,235 Warrants $ 7,092 Black-Scholes Stock price volatility 55.0 % Annual risk free rate 1.7 % (1) The risk-adjusted recurring revenue CAGR is calculated over the five-year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of $1.0 million, resulting in a higher growth rate. (2) Equity volatility based on Evolent’s daily stock price returns for a look-back period corresponding to the time until the second test date. The large one-day stock price drop on November 27, 2019, was excluded from the volatility calculation.

Related Parties (Tables)

Related Parties (Tables)	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Schedule of related parties	The following table presents assets and liabilities attributable to our related parties (in thousands): June 30, December 31, Assets Accounts receivable $ 7,597 $ 8,781 Prepaid expenses - current 801 1,592 Customer advance for regulatory capital requirements, net 39,955 40,000 Prepaid expenses and other noncurrent assets 4,813 2,709 Liabilities Accounts payable $ 7,132 $ 6,429 Accrued liabilities 4,267 2,583 Reserve for claims and performance-based arrangements — 4,264 The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Revenue Transformation services $ — $ 41 $ 1,700 $ 1,200 Platform and operations services 73,885 16,874 141,833 29,818 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) (2,171) 6,657 1,076 14,487 Selling, general and administrative expenses 27 386 97 542

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Reconciliation of revenue from segments to consolidated	The following tables present our segment information (in thousands): Services True Health Intersegment Eliminations Consolidated Revenue For the Three Months Ended June 30, 2020 Services: Transformation services $ 755 $ — $ — $ 755 Platform and operations services 216,544 — (4,169) 212,375 Services revenue 217,299 — (4,169) 213,130 True Health: Premiums — 25,541 (39) 25,502 Total revenue $ 217,299 $ 25,541 $ (4,208) $ 238,632 For the Three Months Ended June 30, 2019 Services: Transformation services $ 1,944 $ — $ — $ 1,944 Platform and operations services 147,599 — (3,077) 144,522 Services revenue 149,543 — (3,077) 146,466 True Health: Premiums — 45,764 (271) 45,493 Total revenue $ 149,543 $ 45,764 $ (3,348) $ 191,959 Services True Health Segments Total For the Three Months Ended June 30, 2020 Adjusted EBITDA $ 10,519 $ (1,480) $ 9,039 For the Three Months Ended June 30, 2019 Adjusted EBITDA $ (8,797) $ 1,123 $ (7,674) Services True Health Intersegment Consolidated Revenue For the Six Months Ended June 30, 2020 Services: Transformation services $ 5,993 $ — $ — $ 5,993 Platform and operations services 432,739 — (10,464) 422,275 Services revenue 438,732 — (10,464) 428,268 True Health: Premiums — 57,928 (279) 57,649 Total revenue $ 438,732 $ 57,928 $ (10,743) $ 485,917 For the Six Months Ended June 30, 2019 Services: Transformation services $ 5,297 $ — $ — $ 5,297 Platform and operations services 297,949 — (6,135) 291,814 Services revenue 303,246 — (6,135) 297,111 True Health: Premiums — 93,140 (536) 92,604 Total revenue $ 303,246 $ 93,140 $ (6,671) $ 389,715 Services True Health Segments Total For the Six Months Ended June 30, 2020 Adjusted EBITDA $ 14,395 $ (1,729) $ 12,666 For the Six Months Ended June 30, 2019 Adjusted EBITDA $ (24,296) $ 1,844 $ (22,452)
Reconciliation of Adjusted EBITDA to net loss	The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Net loss attributable to common shareholders of Evolent Health, Inc. $ (203,521) $ (31,615) $ (282,273) $ (78,354) Less: Interest income 842 842 1,761 1,902 Interest expense (6,293) (3,620) (12,578) (7,182) (Provision) benefit for income taxes 3,904 (1,398) 3,634 (902) Depreciation and amortization expenses (15,778) (15,292) (31,916) (29,558) Equity method investment impairment — — (47,133) — Gain (loss) from equity method investees 25,143 (1,904) 24,731 (2,328) Gain (loss) on disposal of assets — 9,600 (6,447) 9,600 Goodwill impairment (215,100) — (215,100) — Change in fair value of contingent consideration and indemnification asset (756) (100) 3,062 (200) Other income (expense), net 352 (587) 281 (160) Net loss attributable to non-controlling interests — 285 — 2,195 Purchase accounting adjustments — (165) — (761) Stock-based compensation expense (3,703) (4,750) (7,211) (9,287) Severance costs (30) (3,881) (6,133) (14,483) Amortization of contract cost assets (767) (776) (1,207) (1,552) Acquisition costs (374) (2,195) (683) (3,186) Adjusted EBITDA $ 9,039 $ (7,674) $ 12,666 $ (22,452)

Reserves for Claims and Perfo_2

Reserves for Claims and Performance-Based Arrangements (Tables)	6 Months Ended
	Jun. 30, 2020
Insurance [Abstract]
Activity in claims reserves	Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2020, was as follows (in thousands): For the Six Months Ended June 30, 2020 2019 Services (1) True Health (3) Total Services (1) True Health (3) Total Beginning balance $ 54,510 $ 6,640 $ 61,150 $ 17,715 $ 9,880 $ 27,595 Incurred costs related to current year 204,112 41,584 245,696 $ 88,261 $ 73,359 $ 161,620 Incurred costs related to prior year (521) 1,351 830 244 483 727 Paid costs related to current year 167,451 33,538 200,989 73,781 26,473 100,254 Paid costs related to prior year 10,029 6,975 17,004 7,837 8,003 15,840 Change during the year 26,111 2,422 28,533 6,887 39,366 46,253 Other adjustments (2) 4,726 — 4,726 (187) (40,609) (40,796) Ending balance $ 85,347 $ 9,062 $ 94,409 $ 24,415 $ 8,637 $ 33,052 (1) Costs incurred to provide specialty care management services are recorded within cost of revenue in our statement of operations. (2) Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to the True Health segment represent premiums received less administrative expenses related to the reinsurance agreement for amounts in 2019. Refer to Note 10 for additional information about the reinsurance agreement. (3) There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. The number of claims processed for the six months ended June 30, 2020 and 2019 were 170,295 and 206,137, respectively.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2020
Investments [Abstract]
Summary investment holdings	The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of June 30, 2020 and December 31, 2019 (in thousands) were as follows: June 30, 2020 December 31, 2019 Amortized Gross Unrealized Fair Value Amortized Gross Unrealized Fair Value Gains Losses Gains Losses U.S. Treasury bills $ 8,909 $ 492 $ — $ 9,401 $ 10,784 $ 270 $ — $ 11,054 Corporate bonds 1,706 122 — 1,828 1,705 70 — 1,775 Collateralized mortgage obligations 5,695 219 — 5,914 5,472 56 (5) 5,523 Yankees 597 51 — 648 597 30 — 627 Total investments $ 16,907 $ 884 $ — $ 17,791 $ 18,558 $ 426 $ (5) $ 18,979
Investments classified by contractual maturity date	The amortized cost and fair value of our investments by contractual maturities as of June 30, 2020 and December 31, 2019 (in thousands) were as follows: June 30, 2020 December 31, 2019 Amortized Cost Fair Value Amortized Cost Fair Value Due in one year or less $ 836 $ 845 $ 1,807 $ 1,810 Due after one year through five years 16,071 16,946 16,121 16,542 Due after five years through ten years — — 630 627 Total investments $ 16,907 $ 17,791 $ 18,558 $ 18,979
Unrealized loss positions	The Company held the following securities (in thousands) in an unrealized loss position for less than twelve months as of December 31, 2019, and expects to recover the entire cost basis of the security: June 30, 2020 December 31, 2019 Number of Securities Fair Value Unrealized Losses Number of Securities Fair Value Unrealized Losses Collateralized mortgage obligations 1 $ 8 $ — 4 $ 2,075 $ 5

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of cash flow, supplemental disclosures	The following represents supplemental cash flow information (in thousands): For the Six Months Ended June 30, 2020 2019 Supplemental Disclosure of Non-cash Investing and Financing Activities Increase to goodwill from measurement period adjustments/business combinations $ 2,200 $ 596 Class A common stock issued for payment of earn-outs 4,185 800 Accrued property and equipment purchases (26) 166 Consideration for asset acquisitions or business combinations — 16,000 Effects of Leases Operating cash flows from operating leases 6,853 6,542 Leased assets obtained in exchange for operating lease liabilities (1,354) 30,181 Effects of Class B Exchanges Decrease in non-controlling interests as a result of Class B Exchanges — 33,946

Organization (Details)

Organization (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)segment	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments | segment	2
Cash and cash equivalents | $	$ 98,272	$ 101,008	$ 92,821

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle - Operating Segments (Details)	6 Months Ended
	Jun. 30, 2020segment
Accounting Policies [Abstract]
Number of operating segments	2

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle - Restricted Cash and Restricted Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	$ 55,653	$ 28,340	$ 45,158
Current restricted investments	100	704
Current restricted cash	46,794	19,376
Total current restricted cash and restricted investments	46,894	20,080
Non-current restricted investments	615	113
Non-current restricted cash	8,144	8,147
Total non-current restricted cash and restricted investments	8,759	8,260
Cash and cash equivalents	98,272	101,008	92,821
Restricted cash and restricted investments	55,653	28,340	45,158
Restricted investments included in restricted cash and restricted investments	(715)		(812)
Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows	153,210	128,531	$ 137,167	$ 388,325
Collateral for letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	3,610	3,610
Restricted cash and restricted investments	3,610	3,610
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	5,745	5,742
Restricted cash and restricted investments	5,745	5,742
Claims processing services
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	44,886	18,171
Restricted cash and restricted investments	44,886	18,171
Other
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	1,412	817
Restricted cash and restricted investments	1,412	817
Collateral with financial institutions, money market funds
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	1,000	1,000
Restricted cash and restricted investments	1,000	1,000
Bank time deposits
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	4,700	4,700
Restricted cash and restricted investments	$ 4,700	$ 4,700

Basis of Presentation, Summar_6

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle - Notes Receivable (Details) - Passport Note - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 18, 2019
Short-term Debt [Line Items]
Face amount		$ 40,000,000
Interest rate		6.50%	6.50%
Notes Receivable
Short-term Debt [Line Items]
Loans and leases receivable, net amount	$ 40,000,000
Interest receivable	$ 2,700,000

Basis of Presentation, Summar_7

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle - Goodwill (Details) - reporting_unit	Oct. 31, 2019	Jun. 30, 2020
Accounting Policies [Abstract]
Number of reporting units for goodwill testing	3	4

Basis of Presentation, Summar_8

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle - Intangible Assets, Net (Details)	6 Months Ended
	Jun. 30, 2020
Corporate trade name | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Corporate trade name | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	25 years
Technology
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
Provider network contracts | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	4 years
Provider network contracts | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years

Recently Issued Accounting St_2

Recently Issued Accounting Standards (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, right-of-use asset	$ 66,113			$ 72,173
Present value of lease liabilities	74,449
Cumulative effect adjustment	$ (646,864)	$ (1,146,756)	$ (847,072)	(929,047)	$ (1,150,126)		$ (1,189,356)
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member	us-gaap:AccountingStandardsUpdate201602Member
Cumulative transition adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment				2,970
Retained Earnings (Accumulated Deficit)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	$ 537,205	$ 28,345	$ 333,684	251,962	$ (3,270)		$ (50,009)
Retained Earnings (Accumulated Deficit) | Cumulative transition adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment				$ 2,970
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, right-of-use asset						$ 51,400
Present value of lease liabilities						$ 47,400

Transactions - Passport (Detail

Transactions - Passport (Details) - USD ($) $ in Millions	Dec. 30, 2019	Jun. 06, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 18, 2019
Passport Note
Business Acquisition [Line Items]
Interest rate					6.50%	6.50%
Variable Interest Entity | Passport
Business Acquisition [Line Items]
Payments to acquire interest	$ 70
Interest in investment	30.00%			30.00%
Cash consideration in escrow, amount	$ 16.2
Cash consideration released from escrow, amount			$ 16.2
New Medicaid contract not awarded, requirement to acquire ownership, consideration, amount			$ 20	$ 20
New Medicaid contract not awarded, requirement to acquire ownership, term following expiration of current Medicaid contract				12 months
Performance bond amount		$ 25
Variable Interest Entity | Passport | Passport Note
Business Acquisition [Line Items]
Interest rate						6.50%

Transactions - Loss on Disposal

Transactions - Loss on Disposal of Assets (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Business Acquisition [Line Items]
(Gain) loss on disposal of assets	$ 0		$ (9,600)	$ 6,447	$ (9,600)
Vivant
Business Acquisition [Line Items]
(Gain) loss on disposal of assets		$ 6,400

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue		$ 238,632	$ 191,959	$ 485,917	$ 389,715
Transformation services
Disaggregation of Revenue [Line Items]
Total revenue	[1]	755	1,944	5,993	5,297
Platform and operations services
Disaggregation of Revenue [Line Items]
Total revenue	[1]	212,375	144,522	422,275	291,814
Services | Transformation services
Disaggregation of Revenue [Line Items]
Total revenue		755	1,944	5,993	5,297
Services | Platform and operations services | Clinical solutions
Disaggregation of Revenue [Line Items]
Total revenue		161,774	94,573	321,582	191,204
Services | Platform and operations services | Administrative solutions
Disaggregation of Revenue [Line Items]
Total revenue		$ 50,562	$ 49,058	$ 100,616	$ 99,683
[1]	See Note 18 for amounts attributable to related parties included in these line items.

Revenue Recognition - Transacti

Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details) $ in Millions	Jun. 30, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation	$ 108.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	33.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	69.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Short-term receivables	$ 93,066	$ 93,066	$ 71,707
Long-term receivables	740	740	709
Short-term contract assets	2,346	2,346	1,751
Long-term contract assets	47	47	999
Short-term deferred revenue	13,247	13,247	19,828
Long-term deferred revenue	1,338	1,338	$ 1,330
Contract Assets Rollforward
Beginning balance		2,750
Reclassification to receivables, as the right to consideration becomes unconditional		(1,477)
Contract assets recognized, net of reclassification to receivables		1,120
Ending balance	2,393	2,393
Deferred Revenue Rollforward
Beginning balance		21,158
Reclassification to revenue, as a result of performance obligations satisfied		(15,538)
Cash received in advance of satisfaction of performance obligations		8,965
Ending balance	14,585	14,585
Revenue recognized from performed obligations	$ 6,500	$ 7,700

Revenue Recognition - Contrac_2

Revenue Recognition - Contract Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Capitalized Contract Cost [Line Items]
Contract cost amortization			$ 10,272	$ 2,773
Capitalized contract cost, amortization period	5 years		5 years
Bonuses and Commissions
Capitalized Contract Cost [Line Items]
Contract cost assets	$ 4,000		$ 4,000		$ 4,700
Contract cost amortization	400	$ 100	900	200
Contract Fulfillment Costs
Capitalized Contract Cost [Line Items]
Contract cost assets	27,700		27,700		$ 31,800
Contract cost amortization	$ 4,300	$ 1,400	$ 9,400	$ 2,600

Credit Losses - Accounts Receiv

Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, current	59.00%
Accounts receivable, net	$ 104,400
Allowance for doubtful accounts	$ 1,541	$ 41
Past due less than 60 days
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, past due	28.00%
Past due less than 120 days
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, past due	40.00%

Credit Losses - Schedule of Cha

Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Adjustment
Allowance for doubtful accounts, beginning balance	$ (41)
Provision for credit losses	(260)
Charge-offs	1,575
Allowance for doubtful accounts, ending balance	(1,541)
Cumulative transition adjustment
Adjustment
Allowance for doubtful accounts, beginning balance	$ (2,815)

Credit Losses - Investments Hel

Credit Losses - Investments Held at Amortized Cost (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Interest Income	$ 128,000	$ 95,000	$ 266,000	$ 179,000
U.S. Treasury bills
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Interest Income	57,000	61,000	122,000	119,000
Held-to-maturity, allowance for credit loss	0		0
Corporate bonds
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Interest Income	14,000	11,000	29,000	20,000
Collateralized mortgage obligations
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Interest Income	51,000	17,000	104,000	29,000
Yankees
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Interest Income	6,000	$ 6,000	11,000	$ 11,000
Level 2
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Amortized Costs	16,907,000		16,907,000		$ 18,558,000
Level 2 | U.S. Treasury bills
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Amortized Costs	8,909,000		8,909,000		10,784,000
Level 2 | Corporate bonds
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Amortized Costs	1,706,000		1,706,000		1,705,000
Level 2 | Collateralized mortgage obligations
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Amortized Costs	5,695,000		5,695,000		5,472,000
Level 2 | Yankees
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Amortized Costs	$ 597,000		$ 597,000		$ 597,000

Credit Losses - Customer Advanc

Credit Losses - Customer Advance for Regulatory Capital and Notes Receivable (Details) - USD ($)		Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Jun. 18, 2019
Short-term Debt [Line Items]
Customer advance for regulatory capital requirements, net of allowances	[1]	$ 39,955,000	$ 40,000,000
Customer advances, allowances		45,000
Long-term debt, net of discount		299,746,000	293,667,000
Notes receivable, net		$ 1,400,000
Premium ratio to Surplus		10
Prepaid expenses and other assets
Short-term Debt [Line Items]
Notes receivable, allowances		$ 14,000
Other noncurrent liabilities
Short-term Debt [Line Items]
Notes receivable, allowances		$ 37,000
Equity Method Investee | Line of Credit
Short-term Debt [Line Items]
Interest rate		6.50%
Face amount				$ 5,000,000
Long-term debt, net of discount		$ 1,400,000	$ 1,000,000
Loss given default rate assumed		50.00%
Passport Note
Short-term Debt [Line Items]
Interest rate					6.50%	6.50%
Minimum risk-based capital requirement						150.00%
Face amount					$ 40,000,000
Passport Note | Notes Receivable
Short-term Debt [Line Items]
Interest receivable		$ 2,700,000
[1]	See Note 18 for amounts attributable to related parties included in these line items.

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property and Equipment [Line Items]
Total property and equipment	$ 157,389		$ 157,389		$ 140,169
Accumulated depreciation and amortization expenses	(68,834)		(68,834)		(55,014)
Total property and equipment, net	88,555		88,555		85,155
Depreciation expense	7,100	$ 5,700	13,900	$ 10,900
Capitalized computer software, amortization	6,000	4,500	11,600	8,600
Computer hardware
Property and Equipment [Line Items]
Total property and equipment	12,061		12,061		11,604
Furniture and equipment
Property and Equipment [Line Items]
Total property and equipment	3,588		3,588		3,649
Internal-use software development costs
Property and Equipment [Line Items]
Total property and equipment	126,203		126,203		112,501
Total property and equipment, net	77,100		77,100		74,900
Capitalized computer software additions	6,400	$ 8,200	13,700	$ 16,900
Leasehold improvements
Property and Equipment [Line Items]
Total property and equipment	$ 15,537		$ 15,537		$ 12,415

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Impairment Testing (Details) $ / shares in Units, $ in Thousands	Oct. 31, 2019reporting_unit	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)reporting_unit	Oct. 31, 2019$ / shares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2018USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of reporting units for goodwill testing | reporting_unit	3			4
Decrease in average closing price per share due to impairment (in dollars per share) | $ / shares					$ 6.59
Goodwill, impairment testing, percentage share price decrease					43.50%
Number of reporting units, fair value in excess of carrying amount | reporting_unit	1
Impairment		$ 215,100	$ 0	$ 215,100		$ 0	$ 199,800
Goodwill		354,695		354,695			$ 572,064		$ 768,124
Valuation, Income Approach
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 214,300		$ 214,300				$ 431,700

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Goodwill [Roll Forward]
Balance as of beginning of period			$ 572,064	$ 768,124	$ 768,124
Goodwill acquired					3,416
Measurement period adjustments					351
Goodwill disposal	$ (2,200)
Impairment	(215,100)	$ 0	(215,100)	0	(199,800)
Foreign currency translation	(69)				(27)
Balance as of end of period	354,695		354,695		572,064
Cumulative inception to date impairment	575,500		575,500		360,400
Services
Goodwill [Roll Forward]
Balance as of beginning of period			566,359	762,419	762,419
Goodwill acquired					3,416
Measurement period adjustments					351
Goodwill disposal	(2,200)
Impairment			(215,100)		(199,800)
Foreign currency translation	(69)				(27)
Balance as of end of period	348,990		348,990		566,359
True Health
Goodwill [Roll Forward]
Balance as of beginning of period			5,705	$ 5,705	5,705
Goodwill acquired					0
Measurement period adjustments					0
Goodwill disposal	0
Impairment			0		0
Foreign currency translation	0				0
Balance as of end of period	$ 5,705		$ 5,705		$ 5,705

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 403,034		$ 403,034		$ 412,514
Accumulated Amortization	120,121		120,121		104,055
Total future amortization of intangible assets	282,913		282,913		$ 308,459
Amortization of intangible assets	8,700	$ 9,600	$ 18,000	$ 18,700
Corporate trade name
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			13 years 8 months 12 days		14 years 2 months 12 days
Gross Carrying Amount	23,300		$ 23,300		$ 23,300
Accumulated Amortization	5,581		5,581		4,891
Total future amortization of intangible assets	17,719		$ 17,719		$ 18,409
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			16 years 7 months 6 days		16 years 9 months 18 days
Gross Carrying Amount	281,219		$ 281,219		$ 291,519
Accumulated Amortization	50,988		50,988		44,750
Total future amortization of intangible assets	230,231		$ 230,231		$ 246,769
Technology
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			2 years 3 months 18 days		2 years
Gross Carrying Amount	82,922		$ 82,922		$ 82,922
Accumulated Amortization	58,204		58,204		49,760
Total future amortization of intangible assets	24,718		$ 24,718		$ 33,162
Below market lease, net
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			2 years 9 months 18 days		2 years 2 months 12 days
Gross Carrying Amount	1,118		$ 1,118		$ 2,048
Accumulated Amortization	548		548		1,334
Total future amortization of intangible assets	570		$ 570		$ 714
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			3 years 3 months 18 days		3 years 8 months 12 days
Gross Carrying Amount	14,475		$ 14,475		$ 12,725
Accumulated Amortization	4,800		4,800		3,320
Total future amortization of intangible assets	$ 9,675		$ 9,675		$ 9,405

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 14,842
2021	28,701
2022	24,819
2023	22,055
2024	16,171
2024	176,325
Total future amortization of intangible assets	$ 282,913	$ 308,459

Long-term Debt - Credit Agreeme

Long-term Debt - Credit Agreement (Details) - USD ($)	Dec. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2016
Initial Term Loan Facility | Secured Debt
Debt Instrument [Line Items]
Face amount	$ 75,000,000
Credit Agreement | Line of Credit | DDTL Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000,000
Commitment fee percentage	1.00%
Convertible Senior Notes due 2021 | Senior Notes
Debt Instrument [Line Items]
Face amount		$ 125,000,000		$ 125,000,000		$ 125,000,000	$ 125,000,000
Interest rate	2.00%						2.00%
Interest expense		600,000	$ 1,200,000	600,000	$ 1,200,000
Debt issuance costs							$ 4,600,000
Senior Credit Facilities | Secured Debt
Debt Instrument [Line Items]
Interest expense		2,000,000		4,000,000
Debt issuance costs	$ 4,700,000
Non-cash amortization of debt discount and debt issuance costs		$ 500,000		$ 1,100,000
Senior Credit Facilities | Secured Debt | After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary
Debt Instrument [Line Items]
Redemption, call protection premium, percentage	4.00%
Senior Credit Facilities | Secured Debt | After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary
Debt Instrument [Line Items]
Redemption, call protection premium, percentage	3.00%
Senior Credit Facilities | Secured Debt | After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary
Debt Instrument [Line Items]
Redemption, call protection premium, percentage	2.00%
Senior Credit Facilities | Secured Debt | Maximum
Debt Instrument [Line Items]
Term	91 days
Senior Credit Facilities | Secured Debt | Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate	8.00%
Senior Credit Facilities | Secured Debt | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	7.00%

Long-term Debt - Warrant Agreem

Long-term Debt - Warrant Agreement (Details) - Class A Common Stock	Dec. 30, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants agreed to be sold (in shares) | shares	1,513,786
Exercise price of warrants or rights (in dollars per share) | $ / shares	$ 8.05
Period during which warrants or rights exercisable, after maturity of credit agreement	30 days

Long-term Debt - 2025 Notes (De

Long-term Debt - 2025 Notes (Details) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2018USD ($)shares$ / shares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Oct. 24, 2018USD ($)	Oct. 22, 2018USD ($)
Debt Instrument [Line Items]
Carrying amount		$ 299,746,000		$ 299,746,000		$ 293,667,000
Senior Convertible Notes Due 2025
Debt Instrument [Line Items]
Debt issuance costs	$ 5,900,000
Senior Notes | Senior Convertible Notes Due 2025
Debt Instrument [Line Items]
Face amount	$ 172,500,000	172,500,000		172,500,000		$ 172,500,000	$ 22,500,000	$ 150,000,000
Interest rate	1.50%
Proceeds from issuance of debt	$ 166,600,000
Debt issuance costs	$ 3,400,000
Interest expense		700,000	$ 1,300,000	700,000	$ 1,300,000
Conversion price (in dollars per share) | $ / shares	$ 33.43
Initial conversion amount (in shares) | shares	5.2
Carrying amount	$ 100,700,000
Non-cash amortization of debt discount and debt issuance costs		$ 2,100,000	$ 2,100,000	$ 4,300,000	$ 4,100,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100.00%
Repurchase covenant, sale price as a percentage of conversion price	130.00%
Repurchase covenant, trading days, minimum	20 days
Repurchase covenant, consecutive trading days, minimum	30 days
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price	100.00%
Senior Notes | Senior Convertible Notes Due 2025 | Common Stock
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 71,800,000
Debt issuance costs	$ 2,500,000
Senior Notes | Senior Convertible Notes Due 2025 | Class A Common Stock | Common Stock
Debt Instrument [Line Items]
Initial conversion rate per $ 1000 principal amount	0.0299135

Long-term Debt - 2021 Notes (De

Long-term Debt - 2021 Notes (Details) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 31, 2016USD ($)shares$ / shares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 30, 2019
Debt Instrument [Line Items]
Amortization of deferred financing costs				$ 6,079,000	$ 4,600,000
Senior Notes | Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Face amount	$ 125,000,000	$ 125,000,000		125,000,000		$ 125,000,000
Interest rate	2.00%						2.00%
Proceeds from issuance of debt	$ 120,400,000
Debt issuance costs	$ 4,600,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100.00%
Interest expense		600,000	$ 1,200,000	600,000	1,200,000
Amortization of deferred financing costs		$ 300,000	$ 500,000	$ 300,000	$ 500,000
Senior Notes | Convertible Senior Notes due 2021 | Class A Common Stock | Common Stock
Debt Instrument [Line Items]
Initial conversion rate per $ 1000 principal amount	0.0416082
Conversion price (in dollars per share) | $ / shares	$ 24.03
Initial conversion amount (in shares) | shares	5.2

Long-term Debt - Convertible Se

Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Oct. 31, 2018	Oct. 24, 2018	Oct. 22, 2018	Dec. 31, 2016
Senior Convertible Notes Due 2025
Debt Instrument [Line Items]
Carrying value	$ 111,665,000	$ 107,169,000
Unamortized debt discount and issuance costs allocated to debt	60,835,000	65,331,000
Principal amount	$ 172,500,000	$ 172,500,000	$ 172,500,000	$ 22,500,000	$ 150,000,000
Remaining amortization period (years)	5 years 3 months 18 days	5 years 9 months 18 days
Senior Convertible Notes Due 2025 | Level 2
Debt Instrument [Line Items]
Fair value	$ 113,600,000	$ 122,000,000
Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Carrying value	123,697,000	123,237,000
Unamortized debt discount and issuance costs allocated to debt	1,303,000	1,763,000
Principal amount	$ 125,000,000	$ 125,000,000				$ 125,000,000
Remaining amortization period (years)	1 year 4 months 24 days	1 year 10 months 24 days
Convertible Senior Notes due 2021 | Level 2
Debt Instrument [Line Items]
Fair value	$ 109,700,000	$ 111,300,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	Dec. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019
Restricted Cash and Cash Equivalents Items [Line Items]
Operating capital support commitment, maximum amount				$ 3,600,000		$ 4,000,000
Restricted funds				$ 55,653,000		28,340,000		$ 45,158,000
Percent of tax savings to be paid				85.00%
New Mexico Health Connections
Restricted Cash and Cash Equivalents Items [Line Items]
Reinsurance arrangement, capital amount			$ 10,000,000
Reinsurance arrangement, term		15 months
Reinsurance arrangement, percentage of gross premiums ceded		90.00%
Reinsurance arrangement, percentage of claims liability indemnified		90.00%
Reinsurance arrangement, maximum amount of insurance risk as a percentage of premiums ceded		105.00%
Surety Bond
Restricted Cash and Cash Equivalents Items [Line Items]
Loss contingency, estimate of possible loss								$ 25,000,000
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds				$ 5,745,000		5,742,000
Restricted cash and investments				$ 5,700,000		5,700,000
Minimum risk-based capital requirement				150.00%
Variable Interest Entity | Passport
Restricted Cash and Cash Equivalents Items [Line Items]
Interest in investment	30.00%			30.00%
New Medicaid contract not awarded, requirement to acquire ownership, consideration, amount				$ 20,000,000
New Medicaid contract not awarded, requirement to acquire ownership, term following expiration of current Medicaid contract				12 months
Minimum risk-based capital requirement					150.00%
Letter of Credit | Line of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Maximum borrowing capacity							$ 1,800,000
Letter of Credit | Line of Credit | Restricted Cash For Letters Of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds				$ 1,800,000		1,800,000
Letter of Credit | Line of Credit | Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds				$ 1,800,000		$ 1,800,000

Commitments and Contingencies_2

Commitments and Contingencies - Reinsurance Agreements (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Insurance Loss Reserves [Roll Forward]
Reinsurance premiums assumed	$ 0	$ 48,828
Claims assumed	0	41,424
Claims-related administrative expenses	0	8,219
Decrease in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement	0	815
Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period	0	1,243
Reinsurance payments	0	1,235
Receivables for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period	$ 0	$ 823

Commitments and Contingencies_3

Commitments and Contingencies - Concentration Risk (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Concentration Risk [Line Items]
Percentage of cash and cash equivalents held with FDIC participating bank	95.80%		95.80%
Cash and cash equivalents (including restricted cash)	$ 153,210	$ 137,167	$ 153,210	$ 137,167	$ 128,531	$ 388,325
Percentage of cash and cash equivalents held in money market funds	3.80%		3.80%
Percentage of cash held in international banks (less than)	0.40%		0.40%
Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Customer Receivable
Concentration Risk [Line Items]
Concentration risk			56.70%		48.40%
Cook County Health and Hospitals System | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk	19.90%		19.30%
Passport | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk	25.20%	13.20%	23.60%	13.10%
New Mexico Health Connections | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk		13.20%		13.60%

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Lessee, Lease, Description [Line Items]
Restricted funds	$ 55,653	$ 28,340	$ 45,158
Lease Agreements
Lessee, Lease, Description [Line Items]
Letters of credit outstanding, amount	3,600
Restricted funds	$ 3,600	$ 3,600

Leases - Material Office Leases

Leases - Material Office Leases (Details) $ in Thousands	Jun. 30, 2020USD ($)
Lessee, Lease, Description [Line Items]
Future Minimum Lease Commitments	$ 101,868
Arlington, VA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	11 years 7 months 6 days
Future Minimum Lease Commitments	$ 40,203
Letter of Credit Amount Required	$ 1,579
Riverside, IL
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	10 years 9 months 18 days
Future Minimum Lease Commitments	$ 46,053
Letter of Credit Amount Required	$ 232
Louisville, KY
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	6 months
Future Minimum Lease Commitments	$ 0
Letter of Credit Amount Required	0
Prepaid rent	$ 4,100
Pune, India
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	3 years 3 months 18 days
Future Minimum Lease Commitments	$ 2,667
Letter of Credit Amount Required	$ 0
Brea, CA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	1 year 10 months 24 days
Future Minimum Lease Commitments	$ 2,093
Letter of Credit Amount Required	$ 0

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 3,586	$ 3,838	$ 6,642	$ 7,119
Amortization of right-of-use assets	150	0	299	0
Interest expense	1	0	3	0
Variable lease cost	1,465	1,121	2,517	2,576
Total lease cost	$ 5,202	$ 4,959	$ 9,461	$ 9,695

Leases - Maturity of Lease Liab

Leases - Maturity of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
2020	$ 6,039
2021	11,726
2022	9,801
2023	9,376
2024	8,833
Thereafter	56,093
Total lease payments	101,868
Less:
Interest	27,419
Present value of lease liabilities	74,449
Lessee, operating lease, lease not yet commenced, undiscounted amount	$ 200

Leases - Weighted-average Disco

Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)	Jun. 30, 2020
Leases [Abstract]
Weighted average discount rate	6.43%
Weighted average remaining lease term	9 years 7 months 6 days

Earnings (Loss) Per Common Sh_3

Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares
Class of Stock [Line Items]
Net loss	$ (203,521)	$ (31,900)	$ (282,273)	$ (80,549)
Less:
Net loss attributable to non-controlling interests	0	(285)	0	(2,195)
Net loss attributable to common shareholders of Evolent Health, Inc.	$ (203,521)	$ (31,615)	$ (282,273)	$ (78,354)
Weighted-average common shares outstanding - basic and diluted (in shares) | shares	85,349	82,289	84,977	80,820
Loss per common share
Basic and diluted (in dollars per share) | $ / shares	$ (2.38)	$ (0.38)	$ (3.32)	$ (0.97)
Class B Common Stock
Loss per common share
Convertible preferred stock, conversion ratio			1

Earnings (Loss) Per Common Sh_4

Earnings (Loss) Per Common Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	11,626	13,921	11,578	15,233
Exchangeable Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	0	1,080	0	2,129
Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	554	985	376	1,014
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	711	1,495	841	1,729
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	10,361	10,361	10,361	10,361

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 3,703,000	$ 4,750,000	$ 7,211,000	$ 9,287,000
Stock-based compensation capitalized as software development costs	0	0	0	0
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	526,000	891,000	918,000	1,682,000
Selling, general and administrative expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	3,177,000	3,859,000	6,293,000	7,605,000
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	638,000	903,000	1,388,000	2,263,000
Performance-based stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	0	112,000	75,000	222,000
RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	2,006,000	2,630,000	3,862,000	5,060,000
Performance-based RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	0	388,000	0	772,000
LSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 1,059,000	$ 717,000	$ 1,886,000	$ 970,000

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Share-based Awards Granted (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	0	18,000	0	399,000
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	164,000	17,000	1,140,000	518,000
LSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	140,000	0	520,000	720,000

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (3,904)	$ 1,398	$ (3,634)	$ 902
Effective rate	1.90%	(4.60%)	1.30%	(1.10%)
Income tax benefit due to reversal of deferred tax assets valuation allowance	$ 2,300		$ 2,300
Income tax benefit due to difference between federal tax rate in measurement period as compared to the year in which the NOL was carried back	1,400		1,400
Income tax expense, prior year income taxes	600		600
Income tax benefit due to goodwill impairment	$ 800		$ 800
Unrecognized tax benefits					$ 800
Tax receivable agreement, percent of cash savings paid to shareholders			85.00%

Investments In and Advances t_3

Investments In and Advances to Equity Method Investees - Additional Information (Details) - USD ($) $ in Thousands	Dec. 30, 2019	May 24, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Gain (loss) from equity method investees			$ 25,143		$ (1,904)	$ 24,731	$ (2,328)
Gain on disposal of assets			0		9,600	(6,447)	9,600
Impairment of equity method investments			0		0	$ 47,133	0
Passport | Variable Interest Entity
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	70.00%
Payments to acquire interest	$ 70,000
Interest in investment	30.00%					30.00%
Equity method investment, ownership percentage	57.00%
New Medicaid contract not awarded, requirement to acquire ownership, consideration, amount			20,000			$ 20,000
New Medicaid contract not awarded, requirement to acquire ownership, term following expiration of current Medicaid contract						12 months
Global Health | Variable Interest Entity
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		45.00%
Payments to acquire interest		$ 15,000
Equity method investment, ownership percentage		29.00%
Business acquisition, equity interest issued or issuable, number of shares (in shares)		1,577,841
Gain on disposal of assets		$ 9,600
Contingent consideration, liability		$ 5,900
Statutory capital reserves, liquidity guaranteed by investors				300.00%
Equity interest to be transferred				100.00%
Impairment of equity method investments				$ 47,100
Equity Method Investee | Services Agreements
Schedule of Equity Method Investments [Line Items]
Income from long-term services agreement			$ 71,400		$ 11,000	$ 131,300	$ 18,100
Minimum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage			4.00%			4.00%		4.00%
Voting interest percentage			25.00%			25.00%		25.00%
Maximum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage			70.00%			70.00%		70.00%
Voting interest percentage			57.00%			57.00%		57.00%

Investments In and Advances t_4

Investments In and Advances to Equity Method Investees - Schedule of Assets and Liabilities and Maximum Loss Exposure of Unconsolidated VIEs (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jan. 31, 2020	Dec. 31, 2019
ASSETS
Current assets	$ 274,658		$ 228,801
Total assets	1,270,134		1,498,015
Liabilities
Current liabilities	245,122		192,769
Total liabilities	623,270		568,968
Passport | Variable Interest Entity
ASSETS
Current assets	310,977		271,894
Non current assets	701		577
Total assets	311,678		272,471
Liabilities
Current liabilities	177,757		181,206
Non current liabilities	32		40
Total liabilities	177,789		181,246
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure [Abstract]
Investment carrying value	92,797		70,000
Loan and interest receivable	42,687		41,387
Guarantee	25,000		25,000
Maximum exposure	160,484		136,387
Minimum risk-based capital requirement		150.00%
Global Health | Variable Interest Entity
ASSETS
Current assets	0		50,729
Non current assets	0		39,259
Total assets	0		89,988
Liabilities
Current liabilities	0		55,442
Non current liabilities	0		44,650
Total liabilities	0		100,092
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure [Abstract]
Investment carrying value	0		46,456
Loan and interest receivable	0		0
Guarantee	0		0
Maximum exposure	$ 0		$ 46,456

Investments In and Advances t_5

Investments In and Advances to Equity Method Investees - Summarized Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Current assets	$ 274,658		$ 274,658		$ 228,801
Current liabilities	245,122		245,122		192,769
Non-controlling interests	0		0		6,689
Income Statement Related Disclosures [Abstract]
Operating loss	227,469	$ 25,233	252,969	$ 71,879
Net loss	203,521	31,900	282,273	80,549
Net loss attributable to entity	203,521	31,615	282,273	78,354
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Balance Sheet Related Disclosures [Abstract]
Current assets	351,805		351,805		356,085
Non current assets	4,612		4,612		43,744
Current liabilities	202,259		202,259		267,300
Non current liabilities	16,894		16,894		57,599
Non-controlling interests	97,315		97,315		$ 70,535
Income Statement Related Disclosures [Abstract]
Revenue	575,793	30,003	1,194,276	189,975
Operating loss	40,065	254	34,080	(5,874)
Net loss	39,263	340	27,643	(12,185)
Net loss attributable to entity	$ 25,327	$ 75	$ 17,712	$ (347)

Non-controlling Interests (Deta

Non-controlling Interests (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Apr. 30, 2019	May 31, 2015
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests balance as of beginning of period				$ 6,689
Net loss attributable to non-controlling interests		$ 0	$ 285	0	$ 2,195
Reclassification of non-controlling interests					0
Non-controlling interests balance as of end of period		0		0		$ 6,689
Non-controlling Interests
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests balance as of beginning of period		0	50,100	6,689	45,532	45,532
Decrease in non-controlling interests as a result of Class B Exchanges		0	(33,946)	0	(33,946)
Amount attributable to NCI from business combination		0	0	0	6,500
Net loss attributable to non-controlling interests		0	(285)	0	(2,195)
Reclassification of non-controlling interests		0	209	(6,689)	187
Non-controlling interests balance as of end of period		$ 0	$ 16,078	$ 0	$ 16,078	$ 6,689
Class A Common Stock | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)	1.6					3.1
Class B Common Stock
Noncontrolling Interest [Line Items]
Income tax expense, obligations related to exchanges						$ 1,300
Evolent Health LLC
Noncontrolling Interest [Line Items]
Parent's ownership percentage	99.20%					100.00%	99.10%	70.30%

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Liabilities
Warrants and rights outstanding (in shares)	1,513,786	1,513,786
Fair Value, Recurring
Assets
Cash and cash equivalents	$ 4,842	$ 3,698
Restricted cash and restricted investments	1,005	1,004
Total fair value of assets measured on a recurring basis	5,847	4,702
Liabilities
Contingent consideration	3,600	9,883
Warrants	4,900	7,092
Total fair value of liabilities measured on a recurring basis	8,500	16,975
Level 1 | Fair Value, Recurring
Assets
Cash and cash equivalents	4,842	3,698
Restricted cash and restricted investments	1,005	1,004
Total fair value of assets measured on a recurring basis	5,847	4,702
Liabilities
Contingent consideration	0	0
Warrants	0	0
Total fair value of liabilities measured on a recurring basis	0	0
Level 2 | Fair Value, Recurring
Assets
Cash and cash equivalents	0	0
Restricted cash and restricted investments	0	0
Total fair value of assets measured on a recurring basis	0	0
Liabilities
Contingent consideration	0	0
Warrants	0	0
Total fair value of liabilities measured on a recurring basis	0	0
Level 3 | Fair Value, Recurring
Assets
Cash and cash equivalents	0	0
Restricted cash and restricted investments	0	0
Total fair value of assets measured on a recurring basis	0	0
Liabilities
Contingent consideration	3,600	9,883
Warrants	4,900	7,092
Total fair value of liabilities measured on a recurring basis	$ 8,500	$ 16,975

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details)	12 Months Ended
	Dec. 31, 2016
Passport
Business Acquisition [Line Items]
Risk-adjusted recurring revenue compound annual growth rate, number of years	5 years

Fair Value Measurement - Change

Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of beginning of period	$ 16,975	$ 8,800
Additions	0	5,900
Settlements	(3,500)	(800)
Realized and unrealized gains (losses), net	(4,975)	200
Balance as of end of period	$ 8,500	$ 14,100

Fair Value Measurement - Valuat

Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2016	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 16,975		$ 8,500	$ 14,100	$ 8,800
Passport
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted recurring revenue compound annual growth rate, number of years		5 years
Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants	7,092		4,900
Fair Value, Recurring | Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants	7,092		4,900
Fair Value, Recurring | Level 3 | Contingent Consideration Liability | Management estimate | Stock price period
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value			3,600
Fair Value, Recurring | Level 3 | Warrant | Black-Scholes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants	$ 7,092		$ 4,900
Fair Value, Recurring | Level 3 | Warrant | Black-Scholes | Stock price period
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.550		0.618
Fair Value, Recurring | Level 3 | Warrant | Black-Scholes | Annual risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.017		0.003
Fair Value, Recurring | Passport | Level 3 | Contingent Consideration Liability | Real options approach
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 3,700
Fair Value, Recurring | Passport | Level 3 | Contingent Consideration Liability | Real options approach | Risk-adjusted recurring revenue CAGR
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.939
Fair Value, Recurring | Passport | Level 3 | Contingent Consideration Liability | Real options approach | Discount rate/time value | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.048
Fair Value, Recurring | Passport | Level 3 | Contingent Consideration Liability | Real options approach | Discount rate/time value | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.053
Fair Value, Recurring | Passport | Level 3 | Contingent Consideration Liability | Real Options Approach Valuation Technique 2017-2021 | Risk-adjusted recurring revenue CAGR
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted recurring revenue compound annual growth rate, number of years	5 years
Theoretical recurring revenue	$ 1,000
Fair Value, Recurring | Global Health | Level 3 | Contingent Consideration Liability | Monte Carlo simulation | Stock price period
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 5,200
Measurement input	0.800
Fair Value, Recurring | Other Transactions | Level 3 | Contingent Consideration Liability | Management estimate | Adjusted EBITDA
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 983
Measurement input	19,235,000

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Equity Method Investee | Services Agreements
Related Party Transaction [Line Items]
Income from long-term services agreement	$ 71.4	$ 11	$ 131.3	$ 18.1

Related Parties - Assets and Li

Related Parties - Assets and Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2020	Dec. 31, 2019
ASSETS
Accounts receivable	[1]	$ 95,839	$ 75,667
Prepaid expenses - current	[1]	30,473	28,488
Customer advance for regulatory capital requirements, net	[1]	39,955	40,000
Prepaid expenses and other noncurrent assets	[1]	6,437	6,253
Liabilities
Accounts payable	[1]	73,691	37,488
Accrued liabilities	[1]	35,305	33,343
Affiliated Entity
ASSETS
Accounts receivable		7,597	8,781
Prepaid expenses - current		801	1,592
Customer advance for regulatory capital requirements, net		39,955	40,000
Prepaid expenses and other noncurrent assets		4,813	2,709
Liabilities
Accounts payable		7,132	6,429
Accrued liabilities		4,267	2,583
Reserve for claims and performance-based arrangements		$ 0	$ 4,264
[1]	See Note 18 for amounts attributable to related parties included in these line items.

Related Parties - Revenues and

Related Parties - Revenues and Expenses (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue
Total revenue		$ 238,632	$ 191,959	$ 485,917	$ 389,715
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)	[1]	165,812	108,383	341,465	225,824
Selling, general and administrative expenses	[1]	50,511	66,932	105,209	141,770
Affiliated Entity
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)		(2,171)	6,657	1,076	14,487
Selling, general and administrative expenses		27	386	97	542
Transformation services
Revenue
Total revenue	[1]	755	1,944	5,993	5,297
Transformation services | Affiliated Entity
Revenue
Total revenue		0	41	1,700	1,200
Platform and operations services
Revenue
Total revenue	[1]	212,375	144,522	422,275	291,814
Platform and operations services | Affiliated Entity
Revenue
Total revenue		$ 73,885	$ 16,874	$ 141,833	$ 29,818
[1]	See Note 18 for amounts attributable to related parties included in these line items.

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment Reporting - Revenue fro

Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		$ 238,632	$ 191,959	$ 485,917	$ 389,715
Adjusted EBITDA		9,039	(7,674)	12,666	(22,452)
Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		217,299	149,543	438,732	303,246
Adjusted EBITDA		10,519	(8,797)	14,395	(24,296)
Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		25,541	45,764	57,928	93,140
Adjusted EBITDA		(1,480)	1,123	(1,729)	1,844
Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(4,208)	(3,348)	(10,743)	(6,671)
Adjusted EBITDA		9,039	(7,674)	12,666	(22,452)
Transformation services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	[1]	755	1,944	5,993	5,297
Transformation services | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		755	1,944	5,993	5,297
Transformation services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		755	1,944	5,993	5,297
Transformation services | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Transformation services | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Platform and operations services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	[1]	212,375	144,522	422,275	291,814
Platform and operations services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		216,544	147,599	432,739	297,949
Platform and operations services | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Platform and operations services | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(4,169)	(3,077)	(10,464)	(6,135)
Services revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		213,130	146,466	428,268	297,111
Services revenue | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		217,299	149,543	438,732	303,246
Services revenue | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Services revenue | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(4,169)	(3,077)	(10,464)	(6,135)
Premiums
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		25,502	45,493	57,649	92,604
Premiums | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Premiums | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		25,541	45,764	57,928	93,140
Premiums | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		$ (39)	$ (271)	$ (279)	$ (536)
[1]	See Note 18 for amounts attributable to related parties included in these line items.

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Segment Reporting [Abstract]
Net loss attributable to common shareholders of Evolent Health, Inc.	$ (203,521)	$ (31,615)	$ (282,273)	$ (78,354)
Interest income	842	842	1,761	1,902
Interest expense	(6,293)	(3,620)	(12,578)	(7,182)
(Provision) benefit for income taxes	3,904	(1,398)	3,634	(902)
Depreciation and amortization expenses	(15,778)	(15,292)	(31,916)	(29,558)
Equity method investments impairment	0	0	(47,133)	0
Gain (loss) from equity method investees	25,143	(1,904)	24,731	(2,328)
Gain (loss) on disposal of assets	0	9,600	(6,447)	9,600
Goodwill impairment	(215,100)	0	(215,100)	0	$ (199,800)
Change in fair value of contingent consideration and indemnification asset	(756)	(100)	3,062	(200)
Other income (expense), net	352	(587)	281	(160)
Net loss attributable to non-controlling interests	0	285	0	2,195
Purchase accounting adjustments	0	(165)	0	(761)
Stock-based compensation expense	(3,703)	(4,750)	(7,211)	(9,287)
Severance costs	(30)	(3,881)	(6,133)	(14,483)
Amortization of contract cost assets	(767)	(776)	(1,207)	(1,552)
Acquisition costs	(374)	(2,195)	(683)	(3,186)
Adjusted EBITDA	$ 9,039	$ (7,674)	$ 12,666	$ (22,452)

Reserves for Claims and Perfo_3

Reserves for Claims and Performance-Based Arrangements (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)claim	Jun. 30, 2019USD ($)claim
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance	$ 61,150	$ 27,595
Incurred costs related to current year	245,696	161,620
Incurred costs related to prior year	830	727
Paid costs related to current year	200,989	100,254
Paid costs related to prior year	17,004	15,840
Change during the year	28,533	46,253
Other adjustments	4,726	(40,796)
Ending balance	94,409	33,052
Services
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance	54,510	17,715
Incurred costs related to current year	204,112	88,261
Incurred costs related to prior year	(521)	244
Paid costs related to current year	167,451	73,781
Paid costs related to prior year	10,029	7,837
Change during the year	26,111	6,887
Other adjustments	4,726	(187)
Ending balance	85,347	24,415
True Health
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance	6,640	9,880
Incurred costs related to current year	41,584	73,359
Incurred costs related to prior year	1,351	483
Paid costs related to current year	33,538	26,473
Paid costs related to prior year	6,975	8,003
Change during the year	2,422	39,366
Other adjustments	0	(40,609)
Ending balance	$ 9,062	$ 8,637
Number of claims processed, including denied claims | claim	170,295	206,137

Investments - Investment Summar

Investments - Investment Summary (Details) - Level 2 - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	$ 16,907	$ 18,558
Gross Unrealized Gains	884	426
Gross Unrealized Losses	0	(5)
Fair Value	17,791	18,979
U.S. Treasury bills
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	8,909	10,784
Gross Unrealized Gains	492	270
Gross Unrealized Losses	0	0
Fair Value	9,401	11,054
Corporate bonds
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	1,706	1,705
Gross Unrealized Gains	122	70
Gross Unrealized Losses	0	0
Fair Value	1,828	1,775
Collateralized mortgage obligations
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	5,695	5,472
Gross Unrealized Gains	219	56
Gross Unrealized Losses	0	(5)
Fair Value	5,914	5,523
Yankees
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	597	597
Gross Unrealized Gains	51	30
Gross Unrealized Losses	0	0
Fair Value	$ 648	$ 627

Investments - Contractual Matur

Investments - Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Amortized Cost
Due in one year or less	$ 836	$ 1,807
Due after one year through five years	16,071	16,121
Due after five years through ten years	0	630
Total investments	16,907	18,558
Fair Value
Due in one year or less	845	1,810
Due after one year through five years	16,946	16,542
Due after five years through ten years	0	627
Total investments	$ 17,791	$ 18,979

Investments - Unrealized Losses

Investments - Unrealized Losses (Details) $ in Thousands	Jun. 30, 2020USD ($)security	Dec. 31, 2019USD ($)security
Investments [Abstract]
Unrealized loss for less than twelve months, Number of Securities | security	1	4
Unrealized loss for less than twelve months, Fair Value	$ 8	$ 2,075
Unrealized loss for less than twelve months, Unrealized Losses	$ 0	$ 5

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Supplemental Disclosure of Non-cash Investing and Financing Activities
Increase to goodwill from measurement period adjustments/business combinations	$ 2,200	$ 596
Class A common stock issued for payment of earn-outs	4,185	800
Accrued property and equipment purchases	(26)
Accrued property and equipment purchases		166
Consideration for asset acquisitions or business combinations	0	16,000
Effects of Leases
Operating cash flows from operating leases	6,853	6,542
Leased assets obtained in exchange for operating lease liabilities	(1,354)
Leased assets obtained in exchange for operating lease liabilities		30,181
Effects of Class B Exchanges
Decrease in non-controlling interests as a result of Class B Exchanges	$ 0	$ 33,946

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jan. 01, 2021	Sep. 01, 2020	Dec. 30, 2019	Aug. 07, 2020	Jun. 30, 2020	Dec. 31, 2021	Jul. 16, 2020
Molina | Forecast
Subsequent Event [Line Items]
Asset Purchase Agreement, escrow payments		$ 20,000,000
Asset Purchase Agreement, membership payment (up to)						$ 40,000,000
Asset Purchase Agreement, closing payment	$ 7,500,000
Passport | Variable Interest Entity
Subsequent Event [Line Items]
Equity method investment, ownership percentage			70.00%
Interest in investment			30.00%		30.00%
New Medicaid contract not awarded, requirement to acquire ownership, consideration, amount					$ 20,000,000
Subsequent event | An Affiliate of Molina | Passport
Subsequent Event [Line Items]
Real Property Purchase Agreement, consideration				$ 8,000,000
Subsequent event | Passport | Variable Interest Entity
Subsequent Event [Line Items]
Equity method investment, ownership percentage							70.00%